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Apoptosis  or  programmed  cell  death  is  natural  way  of removing  aged cells  from  the  body.  Most  of  the  anti-
cancer  therapies  trigger  apoptosis  induction  and  related  cell  death  networks  to eliminate  malignant  cells.
However,  in  cancer,  de-regulated  apoptotic  signaling,  particularly  the activation  of an  anti-apoptotic  sys-
tems, allows  cancer  cells  to escape  this  program  leading  to  uncontrolled  proliferation  resulting  in tumor
survival,  therapeutic  resistance  and  recurrence  of  cancer.  This  resistance  is a complicated  phenomenon
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Autophagy
Apoptosis evasion
Nuclear transporters, natural
chemopreventive agents
that  emanates  from  the  interactions  of  various  molecules  and  signaling  pathways.  In  this  comprehensive
review  we  discuss  the  various  factors  contributing  to apoptosis  resistance  in  cancers.  The  key  resistance
targets  that  are  discussed  include  (1) Bcl-2  and  Mcl-1  proteins;  (2)  autophagy  processes;  (3)  necrosis
and  necroptosis;  (4) heat  shock  protein  signaling;  (5)  the  proteasome  pathway;  (6)  epigenetic  mecha-
nisms;  and  (7) aberrant  nuclear  export  signaling.  The  shortcomings  of  current  therapeutic  modalities  are
highlighted  and a  broad  spectrum  strategy  using  approaches  including  (a)  gossypol;  (b)  epigallocatechin-
3-gallate;  (c)  UMI-77  (d) triptolide  and  (e) selinexor  that  can be  used  to  overcome  cell  death  resistance
is presented.  This  review  provides  a  roadmap  for  the  design  of  successful  anti-cancer  strategies  that
overcome  resistance  to apoptosis  for  better therapeutic  outcome  in  patients  with  cancer.
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. Introduction
According to the GLOBOCAN factsheet (http://globocan.iarc.fr/),
here were approximately 14.1 million new cancer cases, 8.2 mil-
ion cancer deaths and 32.6 million people living with cancer
within 5 years of diagnosis) in the year 2012 worldwide. Among
hese, 57% (8 million) of new cancer cases, 65% (5.3 million) of
he cancer deaths and 48% (15.6 million) of the 5-year prevalent
ancer cases occurred in the less/under-developed regions of the
orld. Cancer treatment requires a careful selection of one or more
nterventions, such as surgery, radiotherapy, and chemotherapy.
owever, despite major advances in new targeted drug devel-
pment and tailored clinical trial designs, therapy resistance is
ommonly observed in most cancers.
Most cancers harbor signiﬁcant genetic heterogeneity [1], and
atterns of relapse following many therapies are due to evolved
esistance to treatment. While efforts have been made to combine
argeted therapies, a lack of success, rising drug costs, and signiﬁ-
ant levels of toxicity have stymied efforts to effectively treat cancer
ith multi-drug combinations using currently approved therapeu-
ics [2]. Therefore, overcoming therapy resistance mechanisms is
ne of the most sought-after goals in cancer research.
To accomplish this goal, a non-proﬁt organization entitled Get-
ing to Know Cancer launched an initiative called “The Halifax
roject in 2011 with the aim of producing a series of overarch-
ng reviews in each of the areas that are widely considered to be
ancer hallmarks [3]. This novel approach is premised on many of
he insights of genomic sequencing in cancers and it aims to target
any disease-speciﬁc pathways simultaneously. This is proposed
o be done by using low-cost chemistry with little to no toxicity
 to address this heterogeneity (in contrast to the limited number
f actionable targets that have become the norm in combination
hemotherapy).
Our task in the project was to assess the many target choices
hat exist for resistance to cell death, and to identify up to ten
mportant targets as well as prospective non-toxic approaches that
ould potentially be combined to produce a low-toxicity therapeu-
ic approach for this area of concern. So our intent here is to discuss
he inter-relationship between major mechanisms driving resis-
ance to apoptosis in cancer and then to deﬁne a broad-spectrum
herapeutic approach aimed at reaching these important targets
3]. In theory, this approach would then be combined with simi-
ar approaches being recommended for the other hallmark areas
nder review in this special issue.
Apoptosis or programmed cell death is evolutionarily conserved
rocess that plays an essential role in organism development
nd tissue homeostasis [4]. However, in pathological conditions,
articularly cancer, cells lose their ability to undergo apoptosis
nduced death leading to uncontrolled proliferation. Cancer cells
re often found to over express many of the proteins that play
mportant roles in resisting the activation of apoptotic cascade. Sev-
ral mechanisms allow cells to escape programmed cell death and
mong them is the over expression of the anti-apoptotic molecules. Ltd. This  is  an  open  access  article  under  the CC  BY-NC-ND  license  (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Originally most of the research on apoptosis signaling focused on
BH3 pathway proteins leading to acceptance of the Korsmeyers
[5] rheostat model. This model predicted a balance between pro-
survival and pro-death BH3 members. When the balance shifts
toward pro-death signaling, apoptosis occurs, and in instances
when pro-survival molecules outnumber pro-death proteins, sur-
vival signaling is activated leading to pathological conditions such
as cancer and other diseases. With this simplistic model, the drug
discovery arena moved at a rapid pace developing small molecule
inhibitors (SMI) that interfere with the anti-apoptotic pathways
proteins such a B-Cell Lymphoma 2 (Bcl-2), B-Cell Lymphoma extra
large (Bcl-xL, Induced myeloid leukemia cell differentiation pro-
tein (Mcl-1), Bcl-2-like-protein-2 (BCL2L2/Bcl-w) and Bcl-2 related
protein A1 (A1/Bﬂ1). Nevertheless, most of these approaches have
shown little success, and in almost all instances tumor cells become
resistant to such apoptosis inducing drugs [6].
Emerging evidence shows that resistance to apoptosis is multi-
factorial and involves many secondary players that run either
parallel to Bcl-2 signaling or function in complete independence [7].
Here we review the known and emerging pathways that modulate
the apoptosis signaling and discuss strategies to overcome apopto-
sis resistance. We  anticipate that a comprehensive understanding
of the resistance molecules (and the strategies to target them) will
help in the design of clinically successful strategies for cancer in
general and speciﬁcally in patients who show disease relapse.
2. Role of Bcl-2 family proteins in resistance to apoptosis
One of the major hallmarks of human cancers is the intrin-
sic or acquired resistance to apoptosis [8,9]. Evasion of apoptosis
may  contribute to tumor development, progression, and also to
treatment resistance, since most of the anticancer therapies that
are currently available include chemotherapy, and radio- and
immunotherapy (which primarily act by activating cell death path-
ways i.e., apoptosis in cancer cells). Hence, a better understanding
of the molecular mechanisms underlying tumor resistance to apop-
totic cell death is expected to provide the basis for a rational
approach for the development of molecular targeted therapies.
There are two types of apoptosis programs i.e., intrinsic and
extrinsic. The Bcl-2 protein functions through hetero-dimerization
with pro-apoptotic members of the BH3 family to prevent mito-
chondrial pore formation and prevent cytochrome c release and
initiation of apoptosis [10] (Fig. 1). However, there is evidence sug-
gesting that Bcl-2 may  play an oncogenic role through survival
pathways other than its function at the mitochondrial membrane
[11]. It has been reported that Bcl-2 activates nuclear factor-B
(NF-B) by a signaling mechanism that involves Raf-1/MEKK-1-
mediated activation of inhibitor of NF-B kinase subunit beta
(IKK) [12]. Mortenson and colleagues [13] have shown that over-
expression of Bcl-2 increases the activity of AKT and IKK as well
as NF-B transcriptional activity in cancer. While Kumar and col-
leagues [14] found that Bcl-2-induced tumor cell proliferation and
tumor cell invasion were signiﬁcantly mediated by interleukin-8.
S80 R.M. Mohammad et al. / Seminars in Cancer Biology 35 (2015) S78–S103
Fig. 1. The apoptosis pathway: (A) The different paths that a cell can take during the activation of cell death. (B) Apoptosis can be triggered either by external receptor-
dependent stimulus (extrinsic) or through internal (intrinsic) mitochondria-mediated signaling. The extrinsic pathway is initiated by the attachment of death receptors with
their  death initiating ligands, such as FASL, TRAIL or TNF. Consequently, an adaptor molecule, FADD also known as FAS-associated death domain protein, couples the death
receptors and this subsequently leads to the activation of caspase-8. Activated caspase-8 can either directly cleave and activate caspase-7 or caspase-3, thereby promoting
apoptosis. On the other hand the intrinsic pathway is modulated by the activation of BH3-only proteins sensing different types of cell stress, such as DNA damage or ER stress,
and  then activating BAX/BAK at mitochondrial outer membrane (MOM). MOM permeabilization (MOMP) leads to release of different apoptosis-mediating molecules, such
as  cytochrome c, which activates caspase-9. In turn, caspase-9 cleaves and activates caspase-3 and caspase-7, thus triggering apoptotic cell death. Both pathways interface at
the  point of caspase-3 activation. The formation of autophagosome formation requires activation of Beclin 1 which acts as a component of a multiprotein (PI3K) complex. The
crosstalk between autophagy and apoptosis is mediated at least in part by the functional and structural interaction between Beclin 1 and the anti-apoptotic proteins BCL-2
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(nd  BCL-XL. Diverse apoptotic stimuli either intrinsic or extrinsic can lead to casp
aster tumor suppressor p53 has essential roles in both apoptosis and autophagy. A
f  BCL-2, which antagonizes BAX. In addition to apoptosis, p53 can also induce auto
ecently, Tucker and colleagues [15] reported that Bcl-2 over-
xpression leads to the maintenance of cyclin D1a expression, an
ctivity that may  occur through p38 mitogen-activated protein
inase (MAPK)-mediated signaling pathways in human lymphoma
ell lines. Moreover, down-regulation of Bcl-2 could also modulate
he expression of carbonic anhydrase IX (CAIX), vascular endothe-
ial growth factor (VEGF), and pAKT in prostate cancer cell lines [16].
hese studies provide evidence in support for a multi-functional
ole of Bcl-2 in cancer biology that extends beyond its classical
ole in cell survival. However, even though these early studies
ncouraged the application of Bcl-2 targeted drugs in a clinical
etting, most of the ensuing trials have been rather disappoint-
ng [17]. Probably, the drugs are unable to target the entire set of
nti-apoptotic proteins or the inhibition efﬁciency is not robust.
hus, new molecular targets and novel concepts of combination
herapies need to gain access into clinical trials – either in neoad-
uvant/adjuvant or in palliative treatments.
Apoptosis is also deliberated as a stress induced process of cel-
ular communication [18]. In addition to intrinsic and extrinsic
rocesses, there is another pathway that involves T-cell mediated
ytotoxicity and perforin-granzyme-dependent killing of the cell
here granzyme B and granzyme A proteases are responsible for
nducing cell death in this pathway [19]. These intrinsic, extrin-
ic, and granzyme B have different modes of initiation but have
he same outcome: they lead to the activation of a cascade of pro-
eolytic enzymes, members of caspase family [20]. Granzyme A, serine protease, causes cell death by DNA damage by single-
tranded nicks, independent of caspases [21]. The mitochondrial
intrinsic) pathway is regulated by the Bcl-2 family and activatedediated cleavage of Beclin 1 rendering it ineffective as an autophagy inducer. The
ranscriptional level, p53 upregulates BAX, PUMA and BID or reduces the expression
 through TOR inhibition and also through transcriptional activation of DRAM.
by mitochondrial disruption with subsequent cytochrome c release.
Initiators of this pathway include UV irradiation and cytotoxic
drugs. An apoptosome is formed by the interaction of cytochrome c,
Apaf-1, d-ATP/ATP and procaspase-9 with subsequent initiation of
the caspase cascade [22]. Over-expression of Bcl-2 and associated
anti-apoptotic proteins Bcl-xL, Mcl-1, A1/Bf1 and Bcl-w occurs in
substantial subsets of common cancer types that include pancre-
atic, ovarian, lymphoma, multiple myeloma, lung adenocarcinoma,
prostate adenocarcinoma and others. These Bcl-2 proteins can
essentially make cancer cells resistant to a variety of chemothera-
peutic agents and therefore these proteins are currently important
targets for the development of new anti-cancer agents [23,24].
Myeloid cell leukemia-1 (Mcl-1) is a potent anti-apoptotic pro-
tein, a member of the pro-survival Bcl-2 family, its role is emerging
as a critical survival factor in a broad range of human cancers
[25]. Functional studies have conﬁrmed that Mcl-1 is capable of
blocking apoptosis induced by various apoptotic stimuli, includ-
ing chemotherapy and radiation [26]. Mcl-1 is highly expressed at
the protein level in cancer cells and is associated with resistance
to chemotherapeutic agents [27]. It has been demonstrated that
down-regulation of Mcl-1 enhances the induction of apoptosis and
sensitivity of cancer to chemotherapy and radiation [28]. Thus, Mcl-
1 represents attractive molecular target for development of a new
class of cancer therapy for treatment of cancer.
The most potent small molecule inhibitors of the Bcl-2 subfamily
described to date are the Bad-like BH3 mimetics [29]. ABT-737,
one of these mimetics, binds with high afﬁnity (Ki 1 nM)  to Bcl-2,
Bcl-xL and Bcl-w but fails to bind to Mcl-1. It has been demon-
strated that resistance to ABT-737 is linked to high expression
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evels of Mcl-1 and in many instances this resistance can be over-
ome by treatment with agents that down-regulate, destabilize, or
nactivate Mcl-1 [30]. It was also shown that knockdown of Mcl-
 sensitizes human pancreatic cancer cells to ABT-737-induced
poptosis, indicating that Mcl-1 is a relevant therapeutic target
n these cancer cells [31]. Recently, a small molecule agent that
s a speciﬁc inhibitor of Mcl-1 has been developed [32]. The agents
howed activity against a panel of pancreatic and other cancer cell
ines and works through disruption of interaction between Mcl-1-
ax and Mcl-1-Bak with remarkable activity against sub-cutaneous
enograft models of pancreatic cancer.
Highlighting the importance of apoptotic proteins, recently
tuart Schreiber’s group [33] performed genomic and lineage can-
er cell line (CCL) proﬁling to identify cancer dependencies that
re targetable with small molecules and suggested combinations
f compounds that mitigate apoptosis resistance. Their Cancer
herapeutic Response Portal (CTRP) suggests candidate depend-
ncies associated with common oncogenes. The ﬁrst version of
he CTRP resulted from the proﬁling of an Informer Set of Small
olecules (ISSM), many of which target non-altered proteins that
ork in partnership with oncogenes. Exploiting oncogene-induced
ependencies contrasts to an approach based on cancer “hall-
arks” [3,34] without ﬁrst linking these “nononcogene addictions”
o speciﬁc genomic alterations. For example, navitoclax has been
ested in phase I/II clinical trials for small-cell lung cancer [35];
owever, the data suggested that navitoclax might best be tar-
eted to patients harboring catenin cadherin-associated protein 
 (CTNNB1) mutations, which are present in colorectal, hepatocel-
ular, gastric, and endometrial cancers. Indeed it was  demonstrated
hat CTNNB1 mutant CCLs are sensitive to navitoclax in several
ineages, though more strongly in some (e.g., gastric) than others.
he same selectivity was not observed for ABT-199, a Bcl-2-speciﬁc
nhibitor [36], suggesting that inhibition of other Bcl-2 family mem-
ers underlies the differential response. Consistently, Rosenbluh
t al. [37] recently showed that knockdown of Bcl-xL in -catenin-
ctive CCLs impairs proliferation, implicating Bcl-xL as a relevant
arget for navitoclax in CTNNB1 mutant cancers. So drug speciﬁcity
nd selectivity is signiﬁcant, however speciﬁcity should be broad
o cover secondary targets whose presence can lead to resistance
o the initial compound. Such is the argument for a “pan-Bcl-2” SMI
 a compound which may  not bind to all of its targets in the low
anomolar range, but binds to at least Bcl-2 and Mcl-1 to disarm the
ro-survival capacities of these key targets. As such, “dirty drugs”
ay  prove useful to knock out a range of Bcl-2-family members.
his is the reason why natural compound gossypol from cotton
eed has attracted attention for it Bcl-2 inhibitory capacity and has
een developed as an anti-cancer agent for clinical application.
. Autophagy and resistance of cancer
Autophagy serves to maintain intracellular homeostasis
hrough a process that involves lysosomal degradation and
ecycling of unnecessary or damaged cellular components, and
n turn promotes cell survival. Autophagy can prevent cellular
amage caused by chemotherapeutics as it attempts to maintain
ntracellular balance through removal of dysfunctional organelles
nd eliminating cellular stress. It has been suggested that this
emporal survival mechanism may  facilitate chemoresistance as
 byproduct of its function in keeping the cancer cells alive
38]. Indeed, autophagy has been observed to guard cancer cells
gainst apoptosis upon encountering certain anticancer drugs
39–41]. The majority of relevant preclinical studies using numer-
us chemotherapeutics including vorinostat, cyclophosphamide,
nd imatinib have demonstrated that autophagy signiﬁcantly
nhibits the efﬁcacy of several classes of anticancer agents and helpsncer Biology 35 (2015) S78–S103 S81
to drive the acquired resistance [42–44]. Furthermore, accumulat-
ing evidence has indicated that autophagy is involved in adaptation
of cancer cells to chemotherapy [45,46]. These observations suggest
that under chemotherapeutic treatments, autophagy is often acti-
vated as a cytoprotective mechanism for tumor cell to survive the
effects of anticancer drugs which, in turn, may  drive chemoresis-
tance. Therefore, the effects of chemotherapy might be improved
by inhibiting cytoprotective autophagy to enhance the apoptosis of
cancer cells in response to anticancer drugs.
In contrast to its cytoprotective role, autophagy can also lead to
cell death (termed “type II programmed cell death”) when induced
by excessive cellular stress [47]. More importantly, autophagy-
mediated cell death can participate in the upregulation of apoptosis
[48,49], and the inhibition of autophagy has been observed to
reduce apoptosis in some cancer cells [50]. In this regard, apo-
ptosis and autophagic death may engage each other and share
common mechanisms to polarize cellular death response. Further-
more, inhibition of caspase 8 can cause the subsequent activation
of autophagy related gene (Atg) Atg6-Atg7-dependent cell death
pathway [51], suggesting that autophagy-mediated cell death may
serve as a backup mechanism for cell demise in the absence of
apoptotic signaling. Due to its paradoxical role in both cell survival
and cell death, the outcome of autophagy in cancer cells treated
with chemotherapeutic drugs may  therefore depend on the type of
cancer and stimuli, the progress of tumorigenesis, and the apop-
totic status of the cancer cells [52]. As the key mediators in the
autophagic process are either products of tumor suppressor genes
or oncogenes that often cross the regulatory pathways of apoptosis,
clarifying their function during anticancer drug treatment may also
help better understand the process of autophagy-driven chemore-
sistance.
Cell fate dictated by autophagy is regulated by several factors
including beclin-1, PI3K, mTOR, Bcl-2, and p53, which are associ-
ated with many human disorders [53]. Beclin-1, also called Atg6,
is a Bcl-2-homology domain 3 (BH3) protein, that interacts with
Vps34 (a class III PI3K), Vps15 (a myristoylated kinase), and UV
irradiation resistance-associated tumor suppressor gene (UVRAG)
to form a multi-protein interactome that controls the initiation of
autophagy, the autophagosome nucleation [54]. Negative regula-
tors to this process include the anti-apoptotic proteins of the Bcl-2
family, which can interact with beclin-1 and inhibit the function of
the Vps-UVRAG-beclin-1 multi-protein core complex [55].
It has been suggested that increased apoptosis resistance via
anti-apoptotic Bcl-2 family members such as Bcl-2, Bcl-xL, and Mcl-
1 can inhibit autophagy induced by chemotherapy, most likely in
an attempt to protect cells from the autophagic cell death, and
by forming inhibitory complexes with beclin-1 [56]. For example,
sorafenib-activated autophagic death in hepatocellular carcinoma
(HCC) cells is mediated by the reduced expression of Mcl-1. On the
contrary, apogossypolone, a potent anticancer agent that inhibits
Bcl-2 and Bcl-xL, has been shown to abrogate the interaction
between beclin-1 and Bcl-2/xL and induces protective autophagy
in HCC cells [57]. The role of beclin-1 interactome in the crosstalk
between apoptosis and autophagy thus emphasizes that distur-
bances in beclin-1-dependent autophagy can have crucial impact
on the apoptotic resistance in chemotherapy.
The ADP ribosylation factor (ARF) tumor suppressor is expressed
and accumulated in response to mitogenic stimuli conveyed by
oncogenic signals. The majority of ARF localizes to the nucleo-
lus and nucleoplasm, where it antagonizes the E3 ubiquitin ligase
muring double minute 2 (MDM2) to provoke MDM2 degrada-
tion, thereby stabilizing p53 protein [58,59]. A minor fraction of
ARF (smARF) with a smaller molecular weight variant that lacks
the nucleolar localization sequence and preferentially localizes
to mitochondria, has been shown to induce autophagy [60,61].
Once localized to the mitochondria, smARF can bind to Bcl-xL and
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isrupt the complex formation of beclin-1 with Bcl-xL, leading to
n increased ability of beclin-1 to perform its autophagic functions
62,63]. Heat shock protein 70 (hsp70), a molecular chaperone that
s highly expressed in tumor cells, interacts with smARF and reg-
lates the mitochondrial trafﬁcking of smARF, thereby acting as a
ritical regulator of ARF-mediated autophagy [64]. Recently, ARF
as also been identiﬁed as a marker for advanced tumors and a
ack of ARF function is associated with the inhibition of p53 tumor
uppressor function in response to DNA damaging agents as well as
onizing radiation [65,66]. Given that smARF is tightly regulated by
roteasomal degradation and preferentially stabilized by metabolic
tress, it is speculated that it plays both a pro-survival role and a
ytoprotective role in autophagy induced by stress.
Mounting evidence also indicates that ROS are implicated in
utophagy induction in cancer therapy. Importantly, the deregu-
ation of ROS formation during autophagic response is associated
ith cancer initiation, progression, and drug resistance [67,68].
OS, especially mitochondrial ROS, serve as signaling molecules in
nducing autophagy [69]. Atg4, a cysteine protease which cleaves
tg8/LC3 from the outer membrane of autophagosome, is targeted
nd inactivated by ROS, leading to the lipidation of autophagic pro-
ess [70]. At the same time, autophagy contributes to the regulation
f cellular ROS production by eliminating damaged organelles that
ay  produce high levels of ROS which, in turn, limits chromosomal
nstability [71].
The selective clearance of damaged mitochondria or mito-
hondrial autophagy (“mitophagy”) has therefore been suggested
o represent an adaptive response to oxidative stress-mediated
ell death in several cancer cell lines, mitigating accumulated
OS and protecting cell integrity through the removal of ROS-
eaking mitochondria [72]. For instance, anticancer drugs such as
-ﬂuorouracil (5-FU) elicit protective autophagy against cell death,
nd the inhibition of autophagy could enhance apoptosis via ROS
ormation.
Suppressed expression of essential autophagic genes such
s beclin-1 and ATG5 has also been observed to enhance the
xaliplatin-induced ROS production and cell death in Caco-2 cells,
ndicating the role of cytoprotective autophagy in eliminating ROS-
nduced cell death [73]. Furthermore, ROS-induced DNA damage
ctivates the enzymatic activity of poly(ADP-ribose) polymerase-
(PARP-1), which has been demonstrated to induce protective
utophagy through the AMP-activated protein kinase (AMPK) path-
ay and it instigates the resistance of cancer cells to ROS production
y chemotherapeutic drugs [74–76]. Thus, modulating the sensi-
ivity and regulatory mechanism of cells to ROS, such as through
he use of antioxidants, could potentially serve as a strategy in
hemosensitizing and reducing resistance of cancer cells by block-
ng ROS-mediated protective autophagy. Evidence of autophagy
esponding to treatments in cancer cells supports the view that this
hysiological process can help tumors escape drug-induced cyto-
oxicity (as a survival mechanism) or potentiate chemotherapeutic
fﬁcacy (as a cell death pathway). Selective inhibition or induction
f autophagy may  therefore help sensitize resistant tumor cells to
hemotherapeutic treatments.
. In vitro and in vivo necrotic cell death and necroptosis
Necrotic cell death is a cell death process that is morphologi-
ally characterized by a gain in cell volume, swelling of organelles,
lasma membrane rupture and subsequent loss of intracellular
ontents. This is in contrast to programmed cell death (apopto-
is), although it was long thought that necrosis is an uncontrolled
ell death that is characterized by progressive loss of cytoplasmic
embrane integrity, rapid inﬂux of Na+, Ca2+, and water, result-
ng in cytoplasmic swelling and nuclear pyknosis [77]. However,ncer Biology 35 (2015) S78–S103
there is now an increasing realization that necrotic cell death rep-
resents a more programmed form of necrosis, termed necroptosis
[78]. The former leads to cellular fragmentation and the release of
lysosomal and granular contents into the surrounding extracellular
space, with subsequent inﬂammation. A number of toxic chemicals
or physical stresses such as toxins, radiation, heat, trauma, lack of
oxygen due to the blockage of blood ﬂow, and other events can
cause necrosis. When necrotic cells begin to die, cells swell and
holes appear in the plasma membrane and intracellular materials
spill out into the surrounding environment [79].
Necrotic cell death is believed to be a consequence of physico-
chemical stress, such as freeze–thawing or severe hyperthermia,
and thus as accidental and uncontrolled [80]. Interestingly, necrotic
cell death has emerged as an important and physiologically rele-
vant signaling process that seems to contribute to ovulation [81,82],
immune defense [83], death of chondrocytes controlling the longi-
tudinal growth of bones [84], and cellular turnover in the intestine
[85]. In vivo studies indicated that removal of inter-digital cells
in the paws of Apaf 1−/− mice during embryogenesis occurs by a
caspase-independent necrotic-like process [86]. Noteworthy, the
occurrence of necrosis in these in vivo models is mostly deﬁned
morphologically. Several reports also illustrate the occurrence of
necrotic cell death during viral and bacterial infections. For exam-
ple, HIV-1 shows to kill CD4+T lymphocytes by necrosis [87] and
Shigella and Salmonella can induce necrotic cell death of infected
neutrophils and macrophages [88]. Although necrosis has been
thought to be an unregulated process, recent research suggests that
necrosis may  occur in two different pathways in a living organ-
ism. The ﬁrst pathway of necrosis initiation involves oncosis, where
swellings of the cells occur. The cell then proceeds to blebbing, and
it is followed by pyknosis, in which nuclear shrinkage transpires. In
the ﬁnal step of the primary necrosis, the nucleus is dissolved into
the cytoplasm known as karyolysis. The second pathway of necro-
sis involves a secondary form of necrosis that is shown to occur
after apoptosis and budding. In this case, cellular changes of necro-
sis occur in this secondary form of apoptosis, where the nucleus
breaks into fragments, which is known as karyorrhexis.
Unlike necrosis, necroptosis is a more programmed form of
necrosis that has been shown to be a defense mechanism in orga-
nisms against internal pathogens and intracellular infections [89].
Necroptosis was ﬁrst recognized as a caspase-independent form of
cell death that can be triggered by treatment with tumor necrosis
factor (TNF) only in the presence of a pan-caspase inhibitor, such as
zVAD ﬂuoromethyl ketone. Unlike apoptosis, necroptosis requires
that the function of caspase 8 be inhibited or disrupted. Several of
the upstream signaling elements of apoptosis and necroptosis are
shared, and sensitivity to each death pathway is regulated (some-
times in opposing ways) by an overlapping cluster of regulatory
molecules, such as FLICE-like inhibitory protein (FLIP), the deu-
biquitinases A and cylindromatosis and the cellular inhibitors of
apoptosis proteins such as the Baculoviral IAP repeat-containing
protein (cIAP1 and cIAP2). At the molecular level, intracellular
assembly of a highly regulated complex, the necrosome, can be
triggered by death receptors (e.g., tumor necrosis factor receptor
1/TNFR1), by cell-surface toll-like receptors, by DAI  (which may
act as a cytoplasmic viral RNA sensor). The continuing elucidation
of the molecular aspects of various forms of regulated necrosis,
including necroptosis, and the efﬁcient design of combination ther-
apies hold promise for our ability to control regulated necrosis in
clinical settings.5. The role of hsp90 on apoptosis resistance in cancer cells
Heat shock protein 90 (hsp90) is one of the most abundant pro-
teins in eukaryotic cells. It is an enzymatic chaperone molecule with
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TPase activity that is highly active in malignant cells and tissues
hen compared to non-neoplastic cells. In line with its activity
attern and expression proﬁle it has been shown to drive tumor
rogression by enhancing proliferation, migration and metastasis.
n addition, it also confers resistance to programmed cell death
y several mechanisms. By its chaperoning activity, hsp90 stabi-
izes a number of mutated and non-mutated kinases and several
nti-apoptotic factors within the cytosol that overall favor resis-
ance to apoptosis and mostly drive proliferation and resistance of
umor cells to various treatment regimens. These factors include,
ut are not limited to Akt, mutated BRAF, EGFR, JAK2 and the
nhibitor of apoptosis protein survivin. Targeting cytosolic hsp90
licits inhibition of proliferation and depending on the compound
nd tumor cells involved also apoptosis. The kinase, JAK2, was
ecently shown to be an interacting partner of hsp90 in a model
f polycytemia vera [90], a myeloproliferative disorder that almost
lways harbors a JAK2 mutation. In line with the interaction of
sp90 and JAK2, a novel hsp90 inhibitor was shown to disrupt this
nteraction and depleted JAK2 protein levels in vitro and in vivo.
sp90 signaling also appears instrumental in mediating resis-
ance to tyrosine kinase inhibition (TKI) treatment, speciﬁcally with
GFR inhibitory molecules, such as erlotinib and geﬁtinib. These
olecules particularly target mutated EGFR within the intracel-
ular ATP binding domain, especially point mutations in exon 21
L858R) and deletion located in exon 19. With respect to hsp90, Shi-
amura et al. [91] have elegantly shown that in several non-small
ell lung cancer (NSCLC) cell lines geldanamycin (a prototype hsp90
nhibitor) preferentially elicited depletion of mutated EGFR with
ubsequent suppression of p-Akt, causing cell death. Moreover,
7-AAG, a derivative of geldanamycin, more efﬁciently suppressed
utated EGFR compared to the wild-type form. Another important
spect in lung adenocarcinomas is the fact that tumors that are ini-
ially responsive to EGFR inhibition due to selective EGFR mutation
n exon 19 or exon 21 recur eventually because in the presence
f EGFR sensitizing mutations, they generate secondary mutations,
uch as the T790M EGFR mutation, which in turn confers resistance
o erlotinib/geﬁtinib. One option to bypass a T790M mediated resis-
ance is the administration of so called irreversible tyrosine kinase
nhibitors. However, another option appears to be the enzymatic,
ytosolic inhibition of hsp90 by 17-AAG [92]. Shimamura et al. [93]
ave demonstrated in a murine model of lung cancer, harboring
oth an exon 21 (EGFR inhibitor sensitizing mutation) and the resis-
ance mutation (T790M), that 17-DMAG (a derivative of 17-AAG
ith optimized in vivo properties) also reduced tumor growth in
he presence of the T790M mutation, indicating that hsp90 inhibi-
ion may  be a worthwhile strategy to combat EGFR tyrosine kinase
nhibitor resistance. This was further supported by the depletion
f several hsp90 chaperones/downstream molecules in vivo. Given
he unfavorable properties of 17-AAG derived molecules, alterna-
ive molecules are being tested. One of which is Ganetespib that
as recently explored in several lung cancer models, including ones
arboring EGFR inhibitor resistance mediating mutations. Ganete-
pib behaved superiorly compared to 17-AAG and accumulated
ithin neoplastic tissue. Due to the favorable preclinical data it
as also recently assessed in a phase-II-clinical trial [94].
Most of the hsp90 functions are ascribed to its presence and
unction in the cytosol, but recent evidence also suggests that hsp90
s over-expressed in tumor mitochondria and organizes a mito-
hondrial chaperoning network that antagonizes tumor cell death.
n terms of therapeutic applicability, inhibition of hsp90 elicits anti-
ancer activity in tumor cells of various origins and therefore has
merged as a viable treatment target for cancer therapy. In 2007,
ang et al. [95] have unraveled a novel tumor chaperone network
hat is situated in tumor mitochondria. This network consisted
f three major players, hsp90 (as referred now as mitochondrial
sp90; mHsp90), TNF receptor-associated protein 1 (TRAP1) andncer Biology 35 (2015) S78–S103 S83
the cell death promoting protein Cyclophilin-D (Cyp-D). TRAP1 is a
molecule that shares signiﬁcant similarities to hsp90 by exhibit-
ing both structural and enzymatic overlap with hsp90. Akin to
hsp90, TRAP1 reveals ATPase activity and its ATPase activity is
amenable to inhibition by geldanamycin derivatives, such as 17-
AAG. Favoring TRAP1 as a suitable “druggable” target, its expression
levels were increased in malignant neoplasms from lung, colon,
pancreas and breast, prostate and glioblastoma, whereas in non-
neoplastic counterparts expression levels were signiﬁcantly lower
[95]. For example, Matsuda et al. [96] have demonstrated that
-hydroxyisovalerylshikonin, a plant derivative with anti-cancer
activity, depleted TRAP1 levels in mitochondria in DMS114 (lung
cancer) and HL60 (leukemia) cells, respectively. In the matrix of
tumor mitochondria, hsp90 and TRAP1 inhibit mitochondrial per-
meability transition pore (MTP)-dependent cell death initiated by
Cyclophilin-D in tumor cells almost independent of their entity.
Kang and colleagues also elaborated this concept further by devel-
oping two different classes of molecules to speciﬁcally inhibit the
discovered chaperone network in tumor mitochondria. The ﬁrst of
these molecules was a modiﬁed 17-AAG (Ant-GA) molecule that
harbored an Antennapedia linker sequence (Ant), which allowed
the molecule to accumulate in the matrix of mitochondria and
inhibit both mhsp90 and TRAP1. Despite its modiﬁcation Ant-GA
retained its hsp90 inhibitory properties. When incubated, Ant-
GA induces disruption of the mitochondrial membrane potential
of tumor cells, culminating in cell death independent of their
TP53 status, suggesting that a mitochondrial chaperone-targeted
treatment approach does not require presence of wild-type p53
which is amongst the most commonly mutated proteins in can-
cers. To further corroborate the importance of Cyclophilin-D, Kang
et al., [97] also made the case that Cyclophilin-D is implicated
and instrumental for the cell death elicited by Ant-GA, since
cyclosporine-A, an inhibitory molecule of MPT  mediated cell death
mitigated Ant-GA mediated apoptosis. The second molecule that
revealed inhibitory properties of the mitochondrial hsp90 chap-
erone network was a peptide, called shepherdin. Shepherdin was
initially described as a compound that disrupted the interaction
of hsp90 and survivin. This peptide induced cell death in various
cancer cells with a remarkable efﬁcacy without causing apopto-
sis in non-neoplastic cells, such as ﬁbroblasts, epithelial cells or
astrocytes. The initial form of shepherdin had anti-cancer activ-
ity in several skin xenograft models, including prostate cancer.
Consistent with its inhibitory cytosolic properties of hsp90, shep-
herdin treated xenograft tumors exhibited depletion of the hsp90
chaperone client proteins, Akt, and survivin. Most notably, shep-
herdin was  not associated with organ toxicity as provided by a
necropsy analysis of shepherdin treated animals. Consistent with
this notion is the ﬁnding that animals did not exhibit signiﬁcant
weight loss upon administration of the compound. Based on this
determination, it was suggested that shepherdin appears to be a
fairly safe reagent. However, one pitfall may  be the fact that pre-
cise pharmacokinetics were not provided. An engineered shorter
version of shepherdin showed activity against leukemia cells both
in vitro and in vivo [98]. Later on, it was  demonstrated that shep-
herdin also inhibited the mitochondrial hsp90 chaperone network
by interacting directly with TRAP1 and mhsp90. Consistent with
its pharmacodynamics, shepherdin induces a MPT-dependent cell
death speciﬁcally in tumor cells, which akin to Ant-GA requires
the functional presence of Cyclophilin-D. Along those lines, pre-
treatment with cyclosporine-A, an inhibitor of the MPT, attenuated
shepherdin-mediated cell death. In contrast, adenoviral-mediated
over-expression of Bcl-2, that at physiological levels inhibits the
translocation of intermembranous cytochrome c into the cytosol,
did not signiﬁcantly suppress cell death mediated by shepherdin,
suggesting that this reagent acts independent of the Bcl-2 family
of proteins and mainly relies on the MPT  pore in the presence of
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yclophilin-D. All in all, shepherdin represents a prototype of a
double hit” hsp90 inhibitor with tumor speciﬁc pharmacological
ffects both in the cytosol and within mitochondria. Newer class
f sophisticated molecules Gamitrinibs “GA-mitochondrial matrix
nhibitors” have also been tested for their hsp90 inhibitory activity
99]. Gaminitribs are derived from 17-AAG and structurally contain
 mitochondrial linker sequence, which enables them to efﬁciently
ccumulate in mitochondria. Two molecules have received most
ttention: Gamitrinib-TPP and Gamitrinib-G4. They are associated
ith anti-tumor activity in a number of different disease model sys-
ems, including breast cancer, lung cancer, colon cancer, prostate
ancer lymphoma and glioblastoma (also reviewed in [100]). Col-
ectively, a comprehensive understanding of how hsp90 functions
romises not only to provide new avenues for therapeutic inter-
ention, but to shed light on fundamental biological questions of
poptosis evasion.
. The proteasome pathway and apoptosis resistance
Eukaryotic 26S proteasome is a 2.5 MDa  large complex con-
isting of two 19S regulatory particles and one 20S catalytic
ore [101]. Each 19S regulatory particle is composed of the lid,
hich is responsible for recognition and docking of polyubiqui-
inylated proteins into the 20S catalytic core, and the base, which
s in charge of the unfolding and linearization of large proteins.
he 20S catalytic core harbors seven distinct -subunits and -
ubunits arranged in a 7777 stacked barrel, among which
ainly three sets of -subunits, 1 (caspase-like or peptidyl-
lutamyl peptide-hydrolyzing (PGPH)-like), 2 (trypsin-like), and
5 (chymotrypsin-like) are proteolytically active. Unlike common
roteolytic enzymes that contain a catalytic triad, the proteasome
atalytic subunits belong to a special group termed N-terminal
ucleophile hydrolases, which utilizes the side chain of the N-
erminal residue as the catalytic nucleophile [102–104]. All three
atalytic -subunits react with peptide bonds of substrates through
heir OH group of the N-terminal threonine (Thr1), resulting in
rotein being degraded into small fragments of less than 10 amino
cids. It has been well documented that the proteasome is required
or cell cycle progression by regulating the turnover of cyclins and
yclin-dependent kinase inhibitors, and therefore inhibition of pro-
easome function could result in cell cycle arrest. In addition, the
biquitin-proteasomal system can affect cell survival pathways by
egulating the turnover of transcriptional factors responsible for
ell survival or apoptosis such as NF-B, p53, as well as apoptotic
roteins such as the Bcl-2 family members and others [105]. There-
ore, inhibition of the proteasome is linked with the induction of
poptosis.
In tumor tissues, the proteasome activity is up-regulated by
ntracellular oncogenic factors, which render the cancer cells more
ependent on the proteasome than the normal cells. Enhanced
umor cellular proteasome activity in turn promotes the degrada-
ion of tumor suppressor proteins, resulting in cancer cell survival
nd proliferation as well as the development of resistance to apo-
tosis [106]. On the other hand, proteasome activity could be
uppressed by several endogenous inhibitors as well as various
xogenous inhibitors, including some synthetic compounds such
s bortezomib and many natural products such as plant polyphenol
pigallocatechin-3-gallate (EGCG) [107]. Although the mechanism
hat is involved is not clear, proteasome inhibition in cancer cells
s prone to accumulate pro-apoptotic target proteins and induce
ell death. The clinical efﬁcacy of bortezomib in multiple myeloma
nd other hematologic malignancies lends credence to the concept
hat targeting the proteasome, making it a promising strategy for
ancer treatment.ncer Biology 35 (2015) S78–S103
The proteasome also degrades IB, an important inhibitor of
the tumor survival factor NF-B. Many physical (i.e., radiation),
chemical (cancer chemotherapeutic agents), viral and biological
(cytokines, growth factors) agents induce phosphorylation, ubi-
quitination and subsequent degradation of IB by the proteasome,
freeing up NF-B to translocate to the nucleus and modulate genes
involved in proliferation, invasion and tumor survival [108,109].
For example, NFB upregulates the anti-apoptotic protein Bcl-2 and
downregulates the pro-apoptotic protease caspase 8. Therefore, by
inhibiting the proteasome, IB will accumulate which will inhibit
NF-B from promoting tumor survival. The proteasome is also
responsible for degrading the tumor suppressor p53. Many tumor
cells inactivate p53 by over expressing p53 master regulator MDM2
[110]. In human tumors that over express MDM2, the inhibition of
proteasome pathway is predicted to induce tumor cell apoptosis by
accumulating p53. It has been observed that CEP1612, a dipeptidyl
proteasome inhibitor, was  able to rapidly induce apoptosis in differ-
ent human cancer cell lines, including breast, prostate, leukemia,
lung, bone, brain, and head and neck, but not in human normal
ﬁbroblasts and normal breast cells [111].
Proteasome inhibition was  also sufﬁcient to overcome apop-
totic protection by Bcl-2 or Bcr-Abl oncoprotein. Proteasome
inhibition accumulates Bax (but not Bcl-2) protein in mitochon-
dria, resulting in increased ratio of Bax/Bcl-2, associated with
cytochrome c release and apoptosis induction [112]. It has also
been shown that during TNF--induced apoptosis, Bcl-2, but not
Bax, protein is degraded through ubiquitin/proteasome-dependent
pathway [113] which also increased the Bax/Bcl-2 ratio. Therefore,
selectively degrading one or more Bcl-2 family proteins by the pro-
teasome should change the ratio of pro- to anti-apoptotic proteins,
which might contribute to the apoptotic commitment and result in
overcoming resistance.
7. Epigenetics as a mechanism underlying drug resistance
There is uniform recognition of the importance of epigenetics
(heritable non-structural changes in gene expression), as a major
mechanism that can drive acquired resistance to chemotherapy
[114]. For example, epigenetic mechanisms such as non-coding
RNA (microRNAs) and DNA methylation are important drivers
that inﬂuence the chemo-responsiveness of tumors and acquired
drug resistance. Although drug resistance can be overcome using
epigenetic therapies in experimental models, clinical studies of epi-
genetic therapies have highlighted challenges for different cancers,
and there is a need to identify more targeted approaches. Here we
highlight a few epigenetic mediated drug resistance mechanisms
and identify strategies to overcome this challenge.
The breast and ovarian cancer cell line models have provided
some of the earlier insights into the different epigenetic mecha-
nisms underlying drug resistance. Studies have shown that taxane
resistance in breast cancer may  be associated with profound
changes in the expression of apoptotic factors such as caspases.
The gradual development of taxane resistance over a relatively
small number of cell culture passages was shown to correlate with
marked downregulation of caspase 9, 7 and Bcl-2 [115]. Such a
shutdown of the intrinsic pathway was  shown to be associated
with a concomitant up regulation of autophagy. Further, low Bcl-2
expression was seen when cells develop a high level of background
autophagy and this can be associated with collateral sensitivity
to platinum agents, as seen for taxane resistant breast cancer.
Moreover, a high level of background autophagy has also been
demonstrated in breast cancer cell lines with acquired resistance to
anti-endocrine agents such as tamoxifen and also faslodex (fulves-
trant). Resistance to agents such as tamoxifen is a major concern
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hen one considers their widespread use in the management of
reast cancer, both in the prophylactic and adjuvant settings.
Drug resistance in cancer in terms of changes in the entire
pigenome has also been studied. Using the cDNA microarrays
f several cancer cell line models made relatively resistant to
ytotoxic drugs in vitro, candidate genes have been identiﬁed. By
ncorporating the use of agents that can reverse epigenetic methyl-
tion a number of drug resistant cancer cell line models have been
creened and compared with their wild-type drug sensitive coun-
erparts. In this way the major genes that we believe are subjected
o silencing – generally via methylation of the CpG islands in the
romoter region of the gene – and these changes may  often be asso-
iated with the evolution of drug resistance. For example a series of
pithelial ovarian cancer (EOC) cell lines with acquired resistance to
aclitaxel and carboplatin and showed that resistance to paclitaxel,
ften with cross-resistance to carboplatin, occurred with loss of
he G2 checkpoint and apoptosis [116]. Among the featured genes
ncluded the Polo Like Kinase-2 (PLK2) that was down-regulated
ue to acquired methylation in the CpG-island at the 5′ end of
he gene. These studies demonstrated that by increasing levels of
esistance to paclitaxel there was correlation with incrementally
ecreased expression of PLK2 and increasing CpG island methyl-
tion. Based on these studies it was proposed that exposure to
hemotherapeutic stress induces methylation in the CpG island of
peciﬁc “resistance” genes and this seeding effect leads to increas-
ng methylation as the level of resistance increases, a phenomenon
reviously described in cells exposed to 6-mercaptopurine [117]. A
tudy by Matthew et al. [118] looked at the inﬂuence of hypoxia on
hemosensitivity in PLK2-deﬁcient tumors. Here, complete resis-
ance to camptothecin pointed to interplay between the tumor
icroenvironment and PLK2 expression, whereas in the same
xperiments normoxic cells showed increased drug sensitivity. The
ame study also showed that PLK2 can inhibit mTOR signaling
nder the inﬂuence of wild-type p53 control. Furthermore, it was
ound that the cyclin-dependent kinase inhibitor p57kip2 appears
o be down-regulated in drug resistant ovarian cancers [119].
t has also been shown that carboplatin-resistant ovarian can-
er cells show promoter methylation in the CpG island of the
romoter. By silencing otherwise carboplatin-sensitive cells using
iRNA directed against p57kip2, carboplatin resistance was  recapit-
lated which was shown by a reduced apoptotic response in those
ells when challenged with a sub-lethal dose of platinum agents
119]. However, these cell lines studies need validation from ovar-
an cancer patient tissue based expression studies to strengthen the
ole of low p57kip2 and promoter methylation and its association
ith a poor prognosis and evidence of platinum-refractory disease.
An increasing number of genes involved in cell signaling, migra-
ion and adhesion are known to be alternatively spliced and this
rocess appears to be altered during tumor development and pro-
ression. Different spliced forms of genes arise as a consequence
f alternative pre-mRNA processing and are seen in a number of
uman malignancies [120,121]. Splicing processes must recognize
ntron and exon boundaries with accuracy – otherwise there will
e changes in nucleotide sequence at the site of exon joining which
hifts the reading frame with adverse consequences to the pro-
ein coding potential. Splicing is carried out by the “spliceosome”
hich comprises 5 small nuclear RNAs complexed with several
dditional proteins. Alternative splicing is one of the many cell pro-
esses that are commonly changed in the presence of cancer. These
isturbances can result in the production of splice variants with
eoplastic potential and could cause transformation of tumors.
lternative splicing contributes to the large number of proteins
hat can be produced from a much smaller number of genes in the
uman genome. Aberrations in alternative splicing may  also affect
ell proliferation, motility and susceptibility to apoptosis, which
ay  be the result of variant mRNA that is tumor-suppressive orncer Biology 35 (2015) S78–S103 S85
oncogenic and can contribute to carcinogenesis [122]. In particu-
lar, the family of splicing factors – including SC-35 (a member of
the serine rich splicing factors: srsf2) – is recognized to be crucial
in controlling the extent of mRNA splicing into active forms of var-
ious pro-apoptotic genes such as Bax. Head and neck cancer and
ovarian cancer cell lines with acquired resistance to cisplatin have
been shown to under express SC-35. Demethylation analyses have
revealed that the splicing factor, arginine/serine-rich 2 (SRSF2)
gene is silenced via methylation of CpG islands in the promoter
region. Other work looking at epigenetic silencing has highlighted
a number of genes that when silenced can reduce the apoptotic
response of cancer cells to various anticancer agents. These studies
can be used to look for biomarkers of chemo-response by detection
of methylated DNA in cancer patients.
More recently, it has emerged that splicing efﬁciency can be
affected by splicing enhancers which, in turn, interact with regula-
tors that increase exon inclusion such as the SR family of proteins.
SR proteins contain an RNA-binding domain and a characteristic
SRSF2 – otherwise referred to as SC-35 – is located on chromosome
17 and contains a large CpG island. SR proteins control alternative
splicing events in proto-oncogenes and tumor suppressor genes
which leads to profound changes in their cellular activity. Factors
such as SF2/ASF and SC35 are associated with transformation may
be upregulated in some tumors [123]. In a report by Merdzhanova
et al. [124] SC-35 working in conjunction with E2F1 was shown
to be upregulated and required for apoptosis using a panel of
lung cancer cell lines. E2F1, which is an established transcription
factor, is recognized to be stabilized following treatment of cells
with DNA-damaging agents such as cyclophosphamide. The up-
regulation accompanies SC-35 induction and there is evidence that
SC-35 is a direct target of E2F1. Further, SC-35 inhibition was  then
shown to repress apoptosis induced by DNA damaging agents. SC-
35 in its phosphorylated form is necessary for apoptosis following
chemotherapy treatment with cisplatin and is up-regulated follow-
ing this treatment [125,126]. These reported observations have led
to the consideration that down-regulation of SC-35 – and other
splicing factors – as a putative mediator of anticancer drug resis-
tance.
More recently it has been shown that miRNA can have a sig-
niﬁcant effect on the expression of splicing factors such as SC-35.
In drug resistant cell line models that carry signiﬁcant upregula-
tion of miR-221 and miR222 demonstrate marked downregulation
of SC-35, a target gene for both these miRs. Further work should
be focused on the inﬂuence of miR, splicing events and epigenet-
ics on the modiﬁcation of the apoptotic response in drug resistant
cancers.
8. Nuclear transport in apoptosis resistance
Compartmentalization of proteins inside the eukaryotic cell is
an evolutionarily conserved mechanism [127]. Each protein (espe-
cially apoptosis inducers) requires proper sub-cellular localization
to mediate its speciﬁed function [128]. This is especially true for
tumor suppressor proteins (TSPs) that usually reside in cell nucleus
where they exert their function through sequence speciﬁc bind-
ing to DNA, modulation of gene expression, and assessment of the
integrity of the genome [129]. Mislocalization of proteins has been
long recognized to disrupt their function resulting in pathological
conditions including cancer [130]. In eukaryotic cells, the cyto-
sol and the nucleus intercommunicate via nuclear pore complexes
(NPCs) present in the nuclear membrane [131]. NPCs consist of
more than two  dozen different proteins [132]. These nucleoporins
form a channel and regulate the nucleocytoplasmic transport of
various types of RNAs [133], and proteins [134]. The nuclear import
and export of most proteins >40 KDa in size, including membrane
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roteins, occurs through the participation of an evolutionarily con-
erved family of transport proteins belonging to the karyopherin-
amily [135]. Karyopherins- accomplish either nuclear import and
re called importins [136] or nuclear export and are called exportins
137]. Generally, karyopherin-mediated transport occurs through
he NPC, which acts as a gateway into and out of the nucleus [138].
ost of karyopherins- interact directly with their cargoes, but
ay  also be aided by adapter proteins [139]. Karyopherin-,  known
lso as importin-,  is the most-studied adapter protein [140]. All
roteins are synthesized on ribosomes found in the cytoplasm.
uclear proteins must traverse the NPC following their cytoplasmic
ynthesis. While nucleocytoplasmic transport is normally a highly
egulated process, the aberrant expression of karyopherins has
een consistently observed in different cancers and has been linked
o apoptosis resistance [141]. Chromosome maintenance region 1
CRM1) is a karyopherin that exports different protein targets from
he nucleus of the cell [142]. CRM1 is the major exporter of tumor
uppressor proteins (TSPs) and functions by recognizing a leucine
ich nuclear exclusion signal sequences (NESs) in cargo proteins and
ransports them to the cytoplasm in an energy consuming process
hat involves RanGTP binding and hydrolysis to RanGDP [143].
It is well recognized that nuclear localization of TSPs and
heir DNA binding is essential for their regulatory function [144].
ere activation of apoptosis promoting TSPs (such as FOXO3a,
27, Ik  and prostate apoptosis response 4/Par-4) is not sufﬁ-
ient for their proper apoptosis induction as over-expression of
RM1 in cancer cells results in TSPs efﬂux and their functional
nactivation. Supporting this, over-expression of CRM1 has been
ssociated with therapy resistance, particularly resistance to apo-
tosis and poor survival in solid tumors [145]. The prognostic
igniﬁcance of CRM1 in multiple cancers has been established
146]. Its expression is increased in pancreatic ductal adenocar-
inoma, renal carcinoma, non-Hodgkin’s lymphomas, mantle cell
ymphomas, prostate, breast, colon and other cancers. Unlike K-ras
hat is found mutated in >65% of cancers, these TSPs to a large extent
emain wild type [147]. However, till date, there are no clinically
pproved drugs that broadly target the activation of TSPs. These
ultiple lines of evidences support the need for the development
f CRM1 targeted drug for cancer treatment.
Inhibition of XPO1 is one approach to restore nuclear localiza-
ion and activation of multiple TSPs, allowing them to function
roperly [148]. Therefore, targeted inhibition of CRM1 using spe-
iﬁc small molecule inhibitors has been suggested to be a feasible
trategy [149]. Leptomycin B (LMB) was the ﬁrst natural agent
dentiﬁed to irreversibly inhibit XPO1 [150]. LMB  is a secondary
etabolite produced by Streptomyces spp and was originally dis-
overed as a potent anti-fungal antibiotic [151]. LMB  has been
hown to be a potent and speciﬁc nuclear export inhibits XPO1
nd works by alkylating and inhibiting XPO1 through glycosyla-
ion of a cysteine residue (cysteine 529) [152]. Nevertheless, LMB
emonstrated marked toxicity in both preclinical studies and in a
ingle clinical trial and its clinical development discontinued [153].
nother agent, Leptomycin A (LMA) was discovered together with
MB and showed potency twice as that of LMB  [150]. However,
ts clinical utility has not been evaluated. A novel, small molecule,
eversible inhibitor, CBS9106, with XPO1 degrading activity, was
hown to have antitumor effects against multiple myeloma cells,
oth in vitro and in vivo [154]. The development status of this agent
s not known. Recently, novel, orally bioavailable, small molecule,
rug-like, selective inhibitors of XPO1 mediated nuclear (SINE)
ave been described [155]. SINE compounds bind irreversibly to the
ys528 NES recognizing residue in XPO1 and block its ability to bind
o cargo proteins [156]. SINE have been shown to potently inhibit
he growth of multiple cancer cell lines and animal tumor models
uch as acute myeloid leukemia [157], mantle cell lymphoma [158],
nd other hematological malignancies [159]. The anti-proliferativencer Biology 35 (2015) S78–S103
activity of SINE against pancreatic ductal adenocarcinoma and Non-
Hodgkin’s Lymphoma has been demonstrated [160]. Based on these
multiple lines of pre-clinical evidence, the orally bioavailable SINE
KPT-330 have rapidly accelerated toward clinical evaluation in solid
tumors and hematological malignancies.
CRM1 carries essential roles for the normal function of non-
cancerous cells as well. Therefore, the clinical feasibility of any
XPO1 targeted strategy has a number of hurdles. While molecu-
lar mechanism(s) of action of the ﬁrst generation XPO1 inhibitor
LMB  were well deﬁned, the drug proved highly toxic in preclinical
models [161] and was  discontinued in the clinic, the primary reason
being the incomplete understanding and validation of entire sets
of pathways modulated by this master exporter. This is coupled
with a lack of complete evaluation of the effects of XPO1 inhibi-
tion. As recently demonstrated by ours and independent groups,
XPO1 interferes with important and complex processes such
as miRNA processing [162], epithelial-to-mesenchymal transition
[163]. These ﬁndings indicate that more advanced pre-clinical work
in the right models is required to optimize novel XPO1 inhibitors
for applications in cancer and other diseases. Systems biology, par-
ticularly mathematical modeling and network analysis, are new
approaches that can be used to optimize results in areas where
traditional reductionist molecular biology has failed. Mathemati-
cal modeling approaches have been utilized to individually assess
the consequence of XPO1 inhibition on single pathways. Such
approaches have been able to shed light on MAPK/ERK and NF-B
signaling when their nuclear export is blocked, highlighting that the
technology, if used correctly, can be applied successfully in XPO1
related research. However, there are no studies to date that have
evaluated the differences in the effect of XPO1 inhibition on re-
alignment of proteins in cancer versus normal cell nuclei in any
kind of global context. Major unanswered questions remain as to
whether there are differences in cellular responses between cell
types (cancer with aberrant genome versus normal cells with nor-
mal  genome versus precancerous lesions). Performing such studies
at the systems level will undoubtedly lead to the optimization of
XPO1 inhibitor therapies in the clinic, as well as in the design of
novel strategies targeting nuclear transport.
9. Apoptosis resistance in different cancers
9.1. Apoptosis resistance in glioblastoma
Among all brain tumors, glioblastoma multiforme (GBM) is the
most prevalent brain tumor in humans [164]. It is classiﬁed as grade
IV astrocytoma by the World Health Organization (WHO) [165].
Various molecular alterations are responsible for development of
GBM. Apoptosis resistance plays one of the key roles in tumorigen-
esis and sustains malignant progression in GBM. GBM patients have
a poor prognosis with a median survival of 14.6 months. Surgery,
radiotherapy, and the alkylating chemotherapy with TMZ  are the
standard ﬁrst line treatment for GBM patients [166,167]. Combina-
tion therapeutic strategy with radiotherapy and TMZ  signiﬁcantly
improves the median survival, 2 to 5 years, compared to radio-
therapy alone in patients with newly diagnosed GBM [168,169].
Therapeutic effect of TMZ  on GBM cells depends on the epige-
netic silencing of the O6-methylguanine-DNA-methyltransferase
(MGMT) gene by promoter methylation [170]. MGMT  counteracts
chemotherapy-induced DNA damage by restoring the structural
integrity of O6-alkylated bases. Unmethylated MGMT  promoter is
frequently observed in glioblastoma patients and these seem to
respond poorly to TMZ  treatment [171]. Until now there has been
no alternative drug treatment for GBM. Thus, understanding the
molecular mechanisms that mediate cellular survival and apopto-
sis resistance will enable us to exploit the key players to design
better drug combinations for targeted therapies for GBM patients.
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Erlotinib and geﬁtinib, which are two epidermal growth fac-
or receptor (EGFR) tyrosine kinase inhibitors, have been evaluated
or GBM treatment. The low molecular weights of these inhibitors
nable them to cross the blood–brain barrier (BBB). Recent stud-
es show that GBM patients with ampliﬁed or overexpressed EGFR
esponded better to erlotinib than patients with normal EGFR levels
172] and the response depended on low levels of Akt activation.
o, Akt phosphorylation may  be a direct result of increased EGFR
ctivity. Thus, treatment with EGFR inhibitors can show better clin-
cal responses. Clinical studies indicated that treatment with single
yrosine kinase inhibitor like erlotinib could not effectively inhibit
urvival signaling because many other RTK were co-activated in
BM cells [173,174]. Two other receptors, platelet-derived growth
actor receptor (PDGFR) and c-Met or hepatocyte growth factor
eceptor (HGFR), are also involved in EGFR function and in main-
aining downstream pathway activation [175]. This suggests that
arefully designed combination of inhibitors with limited toxicity
roﬁles and maximal additive or synergistic effects may  provide
ore beneﬁcial therapeutic effects [176]. TMZ  causes cell cycle
rrest at G2/M phase and EGFR inhibitors prevent cells from pro-
ressing beyond G1 and may  therefore compromise the activity of
ther cell cycle-speciﬁc agents [177]. As the EGFR tyrosine kinase
nhibitors show low toxicity, higher dose can be applied, but it may
e difﬁcult to predict the functionally active drug in GBM patients.
owever, the lack of availability of post-treatment tumor tissue for
alidation of target inhibition results in uncertainties regarding the
ufﬁcient inhibition of the EGFR signaling.
Many inhibitors of the anti-apoptotic members of the Bcl-2 fam-
ly have been developed and several of them are under preclinical
r clinical trials [178]. Although some of the inhibitors have been
ested, only one compound has reached the clinical trial in GBM
atients. Brain tumors that overexpress anti-apoptotic Bcl-2 and
cl-xL proteins can be treated with their inhibitors. ABT-737, a
ecently developed Bcl-2 inhibitor, is known to induce apopto-
is in glioblastoma cells both in vitro and in vivo by releasing the
ro-apoptotic Bax protein from its binding partner Bcl-2 [179]. ABT-
73 can sensitize tumor cells to the tumor necrosis factor-related
poptosis-inducing ligand (TRAIL) as well as to other anti-cancer
rugs. But, cells with higher expression of Mcl-1, which is an anti-
poptotic protein of the Bcl-2 family, are found to be less responsive
o ABT-737 treatment. So, combination therapy with inhibitors of
cl-1 and Bcl-2 can be a novel strategy to treat GBM. Recent inves-
igations indicated that the BH3-binding compound HA14-1 can
nhance the sensitivity of human glioblastoma cells to both radio-
herapy and chemotherapy [180]. Gossypol (AT-101), which is a
ulti-targeting polyphenol derived from cotton plant, is so far the
nly Bcl-2 targeting compound tested in clinical trials for treatment
f GBMs [181]. Gossypol binds to the BH3 pocket of anti-apoptotic
cl-2 proteins [182] as well as to other target proteins [183]. Studies
uggest that administration of gossypol (20 mg/day) is well toler-
ted in patients and it has a low but measurable response rate. A
hase II trial of gossypol in recurrent GBM is underway to detect its
fﬁcacy against tumor progression and also its toxicity.
The inhibitors of apoptosis (IAP) family proteins like XIAP, cIAP1,
IAP2, ILP2, ML-IAP, and survivin are well known for inhibition of
poptosis in GMB  [184,185]. The IAP family proteins are currently
nown as the baculoviral inhibitors of apoptosis repeat containing
BIRC) proteins. These BIRC proteins can inhibit apoptosis by mod-
lating the activity of different caspases like caspase-9, caspase-7,
nd caspase-3, which are actively involved in intrinsic pathway of
poptosis in human glioblastoma [186]. In most GBM patients, high
evels of BIRC proteins have been detected. Therefore, targeting
IRC proteins to make active caspases available for induction of
poptosis is now an established approach in developing strategy
or controlling growth of human glioblastoma cells [187]. Many
reclinical trials have been carried out with several small moleculencer Biology 35 (2015) S78–S103 S87
inhibitors directed to BIRC proteins to identify a potential agent
capable of inducing apoptosis in different cancers [188]. However,
very little research has been performed with BIRC inhibitors in
GBM. A recent report showed that BIRC-4 (XIAP) inhibitors syn-
ergize with radiation to increase glioblastoma cell apoptosis [189]
and targeting BIRC proteins can sensitize cells to TRAIL for induc-
tion of apoptosis [190]. Recent investigations also indicated that the
endogenous BIRC inhibitor Smac can signiﬁcantly increase the anti-
cancer efﬁcacy of TRAIL in an intracranial glioblastoma xenograft
model [191]. Also the use of inhibitors of histone deacetylase and
of the proteasome in clinical trials (targeting speciﬁc, but poorly
characterized aspects of apoptosis) are ongoing at the moment. The
versatility and applicability of these preclinical studies will even-
tually contribute to elucidation of the molecular mechanisms of
chemoresistance, which should ultimately result in the identiﬁca-
tion of more effective therapeutic strategies for avoiding apoptosis
resistance in GBM.
9.2. Resistance to apoptosis in melanoma
Melanoma is considered the most aggressive form of skin
cancer, derived from activated or genetically altered epidermal
melanocytes. Human malignant melanoma is a highly metastatic
cancer that is markedly resistant to conventional therapy such
as dacarbazine or TMZ. The RAF/MAP kinase pathway has
attracted attention because activating mutations of the BRAF ser-
ine/threonine kinase has been detected in more than 50% of
melanomas. Other mutations occur in NRAS, MEK1, MEK2 as well
as c-Kit. Activation of c-Kit results in the stimulation of MAPK
and PI3K/AKT pathways resulting in both proliferative and survival
advantage. Several other signal transduction pathways have been
found to be constitutively active or mutated in other subsets of
melanoma tumors including NF-B. Raf inhibitors in general and
speciﬁc BRAF inhibitors, including vemurafenib, frequently elicit
therapeutic response. However, durable effects are often limited
by ERK1/2 pathway reactivation via poorly deﬁned mechanism.
Resistance to apoptosis using BRAF speciﬁc inhibitors is mediated,
in part, by the presence of NRAS mutation and required switch in
activation of RAF isoform, CRAF. Furthermore, rebound melanoma
growth after initial treatment with BRAF speciﬁc inhibitors is asso-
ciated with elevated activation of PI3K/Akt pathway.
It has been shown that the Bcl-2 positive regulator NF-B is a key
player in human melanoma tumorigenesis. Canonical NF-B acti-
vation in melanoma cells is associated with increased survival and
proliferation. In human melanoma, a number of NF-B-dependent
chemokines are constitutively expressed at high levels including
CXC ligand 8 (CXCL8 or IL8), interleukin-8 [192], CXCL1, melanoma
growth stimulatory activity or MGSA [193], CCL5 (regulated on acti-
vation), normal T expressed and secreted, or RANTES [194] and
CCL2 (monocyte chemotactic protein-1), or MCP1 [195]. In late
stages of metastatic melanoma, hyperactivated NF-B inhibits pro-
apoptotic pathways through the upregulation of (i) tumor necrosis
factor receptor-associated factor-1 (TRAF-1) and TRAF-2 [196]
to inhibit the TNF-R1/caspase-8-mediated pro-apoptotic pathway
TRAIL decoy receptor, inhibiting the TRAIL-mediated cell-death
pathway [197,198], and (iii) Fas-associated phosphatase-1 (FAP-1)
[199], which down-regulates FAS-R trafﬁcking from cytoplasm to
membrane [200]. Furthermore, in late stage metastatic melanoma,
activation of NF-B also enhances several anti-apoptotic molecules
such as inhibitor of apoptosis (IAP) [201], caspase-8 (FLICE) and
inhibitory protein (FLIP) [202]. NF-B also promotes Myc  activ-
ity [203] and the cell cycle regulatory proteins, cyclin D1 and
cyclin dependent kinase 2 (CDK2) [204], which further contribute
to melanoma tumor growth.
More than 50% of melanoma cells harbor mutations in BRAF
signaling protein [205]. BRAF is part of the Raf family of
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erine/threonine kinases, which are effectors of the small GTPase
AS in the ERK/MAPK pathway. This pathway is activated by sev-
ral membrane-bound receptors such as receptor tyrosine kinases
nd G-protein-coupled receptors. BRAF transduces signals through
itogen activated protein kinase (MAPK) [206,207]. MAPK pro-
otes regulation of cell growth, survival and differentiation [208].
anonical activation of the MAPK pathway occurs when growth
actor-growth factor receptors bind which leads to the activation
f a RAS family member, any of the three isoforms H, N, and
-RAS. Activated RAS then binds and activates multiple effector
roteins, including the three Raf members (ARAF, BRAF and CRAF),
eading to subsequent activation of a cascade of kinases including
EK1/2 and ERK1/2. Activated ERK in turn speciﬁcally phospho-
ylates a number of nuclear and cytoplasmic substrates including
he ETS transcription factor, which has the net effect of provid-
ng a pro-growth and pro-survival signal [209]. Concurring with
hese assumptions, Erk1/2 signaling has been shown to protect
elanoma cells against TRAIL-induced apoptosis by inhibiting the
elocation of Bax from the cytosol to mitochondria and that this
ay  reduce TRAIL-mediated release of Smac/DIABLO and induction
f apoptosis.
.3. Apoptosis resistance in pancreatic ductal adenocarcinoma
With mortality rates almost mirroring incidence rates, pancre-
tic ductal adenocarcinoma (PDAC) is among the most lethal of all
ancers. It causes more than 170,000 deaths worldwide and is the
ourth leading cause of cancer related deaths in the United States
aking it a deadly disease in urgent need for newer treatment
pproaches [210]. PDAC tumors are very heterogeneous and carry
lterations in many critical pathways (harbor a robust biological
etwork) rendering the design of therapy against a single path-
ay unrealistic [211]. The major reasons for this dismal outcome
nclude, lack of early detection markers [212], invasive behav-
or [213] and intrinsic resistance to therapeutic treatments [214].
ecently, several studies have identiﬁed a highly resistant sub-
et of PDAC cancer stem cells (CSCs) with self-renewal capacity
nd propensity to undergo epithelial to mesenchymal transition
215]. Additionally, the low clinical efﬁcacy of different regimens in
DAC has been attributed to the lack of drug penetrance due to the
resence of high desmoplastic stroma that supports a low tumor
asculature [216]. Thus, holistic studies are needed that identify
ffective regimen against PDAC CSCs, and key molecules that pro-
ote desmoplastic stroma in PDAC will provide biomarkers and
otential targets to overcome chemo resistance and disease recur-
ence.
De-regulated apoptosis signaling mechanisms have been
ttributed as one of the major causes for the drug resistance. Pan-
reatic cancer has been shown to over-express Bcl-2 and its family
embers. Therefore, blockade of Bcl-2 activity should become a
ovel therapeutic strategy for pancreatic cancer. Many groups have
een working to develop anticancer drugs that block the function
f Bcl-2 members. Earlier Wang and colleagues have successfully
emonstrated that targeted inhibition of Bcl-2 can suppress PDAC
rowth in vitro and in vivo [217]. Very recently, Abulwerdi et al., [32]
xploited Mcl-1 as a therapeutic target using small molecule drugs
n PDAC. Both these studies collectively prove that targeted inhibi-
ion of BH3 family proteins could be a viable therapeutic strategy
gainst PDAC.
.4. Apoptosis resistance in colon cancerColorectal cancer is among the common forms of cancer world-
ide and ranks third among the cancer-related deaths in the US and
ther Western countries. It is common to both men  and women,
onstituting 10% of new cancer cases in men  and 11% in women.ncer Biology 35 (2015) S78–S103
Despite recent advancement in therapeutics, the survival rates
from metastatic are less than 5%. Growing evidence supports the
contention that epithelial cancers including colorectal cancer, the
incidence of which increases with aging, are diseases driven by the
pluripotent, self-renewing cancer stem cells (CSCs). Dysregulation
of Wnt, Notch, Hedgehog and/or TGF- signaling pathways that
are involved in proliferation and maintenance of CSCs leads to the
development therapy resistance.
The loss of heterozygosity (LOH) at the bcl-2 gene locus and
the expression of the bcl-2 gene has been examined in colorec-
tal carcinoma cell lines and carcinoma tissues. LOH at the bcl-2
locus was detected in 60% (6/10) of colonic carcinomas, all of
which were well differentiated adenocarcinomas, whereas LOH
was not seen in poorly differentiated ones. Further, tree colorectal
carcinoma cell lines, all of which were derived from poorly differ-
entiated adenocarcinomas, expressed considerable levels of bcl-2
mRNA and protein. These results suggest that LOH at the bcl-2
locus is frequently associated with well differentiated adenocar-
cinomas of colon, and bcl-2 overexpression has implications for
the development of poorly differentiated adenocarcinomas of the
gastrointestinal tract.
Colon tumors have been shown to exploit the lymphocyte
death program by expressing FasL [218]. This may  enable colon
tumors to mount a “Fas counterattack” against antitumor lym-
phocytes, impairing antitumor immune responses. FasL-expressing
colon tumor-derived cell lines can trigger Fas-mediated apoptosis
of co-cultured T cells in vitro. FasL expressed in esophageal cancer
has been signiﬁcantly associated with apoptosis and depletion of
tumor-inﬁltrating lymphocytes (TIL) in vivo. FasL may  also facilitate
metastatic colonization of Fas-sensitive organs such as the liver,
by inducing apoptosis of target organ cells. Normal colonic epithe-
lial cells express Fas and are relatively sensitive to Fas-mediated
apoptosis. By contrast, colon tumor-derived cell lines are usually
resistant to induction of Fas-mediated apoptosis, and colon cancer
cells frequently coexpress Fas and FasL. The mechanisms allow-
ing resistance to Fas-mediated apoptosis are complex, and defects
have been identiﬁed at several levels of Fas signal transduction. The
“Bcl-2 rheostat” may  be pitched against apoptosis in colon cancer,
in as much as over-expression of Bcl-2, downregulation of Bak, and
mutation of Bax are common defects in colon tumors. Caspase-1
is also downregulated in colon cancer. The high frequency of p53
mutations in late-stage cancers may  also inhibit Fas signaling. Fun-
damental defects in apoptosis signaling may  contribute to both
immuno- and chemoresistance in colon cancer and allow expres-
sion of FasL to counterattack antitumor lymphocytes.
9.5. Apoptosis resistance in prostate cancer
With an estimated 233,000 new cases diagnosed and 29,480
deaths, prostate cancer is considered as the top major cause for can-
cer related deaths in the United States. Hormone ablation therapy
is used to manage early stage disease, however, in majority of cases,
prostate cancer becomes castrate resistant [219]. The disturb-
ance in apoptosis pathway activation in prostate cancer therapy
resistance has been clearly deﬁned [220]. More speciﬁcally, Bcl-
2 over-expression has been shown to promote androgen ablation
resistance [221]. Aside from disturbed apoptotic machinery, a num-
ber of studies have demonstrated that lack of autophagy activation
may  also contribute to chemo- and hormone therapy resistance in
prostate tumors [222,223]. Nevertheless, there are reports showing
that autophagy pathway activation may  even promote apopto-
sis resistance and this has been linked to therapy resistance of
prostate cancer [224,225]. Therefore, it is needless to say that
autophagy modulators have been shown to resensitize prostate
cancer cells to radiation or chemotherapy [226,227]. Similarly, a
number of Bcl-2 inhibitors have shown to reverse prostate cancer
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hemoresistance [228,229]. Mcl-1 inhibition has also been shown
o re-sensitize prostate cancer cells to different chemotherapeutics
nd targeted therapies [230–232]. Besides Bcl-2 and Mcl-1 over-
xpression, TRAIL induced apoptosis resistance in prostate cancer
as also been reported [233]. The development of TRAIL resistance
s both genetic and epigenetic [234] that manifests in apoptosis
esistance. Collectively, these studies clearly prove that sensitivity
o therapeutics (chemo-, hormone, radio- or targeted) is directly
orrelated to the presence of functional apoptotic machinery.
.6. Apoptosis resistance in breast cancer
Breast cancer is the major cause for female cancer mortality
n the western world (GLOBACON). Despite the advances in early
etection and the greater understanding of the molecular path-
ays underlying breast cancer biology, a major fraction of patients
ave recurrent disease that becomes refractory to most of the
vailable therapies [235]. Systemic therapies include the use of
ytotoxic, hormonal, and immunotherapy is usually used in the
djuvant, neoadjuvant, and metastatic settings. While these sys-
emic agents are active in the majority of primary breast cancers
nd also to a great extent in metastatic cases, nevertheless, after
 variable period of time, progression occurs. Resistance to thera-
eutics in breast cancer is multi-factorial. It involves disturbances
n the apoptotic machinery, p-glycoprotein and the multidrug
esistance protein family, HER-2/neu gene ampliﬁcation and pro-
ein expression, along with the expression of additional members
f the epithelial growth factor receptor family, DNA ploidy, p53
ene mutations, cyclin E and p27 dysregulation that cumulatively
rive the development of cancer stem cells [236]. A number of
tudies have linked breast cancer drug resistance to disturbed
r over-expression of pro-survival factors including Bcl-1, Mcl-1
nd other BH3 family members [237]. This is conﬁrmed from the
bservation that BH3 mimetic ABT-737 can sensitize BH3 protein
ver-expressing breast cancer cells [238]. Studies have also linked
isturbed proteasome signaling to breast cancer chemo and radio
esistance [239]. These ﬁndings become particularly relevant as
roteasome inhibitor bortezomib treatment causes suppression of
DRs leading to induction of apoptosis in breast tumor models
240]. In summary these studies prove that the inherent resistant
raits of breast cancer are associated with malfunctioning of the
poptosis signaling. Targeting the different pathways that either
nduce apoptosis or suppress the pro-survival signaling is expected
o resulting in overcoming drug resistance to various therapies.
.7. Apoptosis resistance in leukemia’s (focus on chronic
ymphocytic leukemia and acute promyelocytic leukemia)
Chronic lymphocytic leukemia (CLL) is the most common B-
ell malignancy in the Western world and is characterized by the
ccumulation of mature CD5 positive B lymphocytes in peripheral
lood, bone marrow, and lymphoid organs [241]. CLL disease is
enerally associated to apoptosis resistance. A combination of alter-
tions in the apoptotic machinery as well as micro-environmental
urvival signals within the CLL cells cause a cell death resistance.
ecent studies suggest that most CLL clones include activated cells
hat proliferate at appreciable rates [242,243]. Thus, the balance
etween proliferation and cell death is extremely within patients
nd reﬂects the different disease progression [244].
In CLL, defects in the intrinsic and extrinsic apoptotic path-
ays have been described. B-cells can be resistant to both CD95/Fas
245] and TRAIL death receptors induction [246]. The intrinsic, or
itochondrial, pathway is regulated by the Bcl-2 family proteins,
lassiﬁed into anti-apoptotic (Bcl-2, Bcl-XL, Bcl-w, Mcl-1, A1) and
ro-apoptotic (Bax, Bak, Bim, Bad, Bid, Hrk, Noxa, Puma) mem-
ers [247]. In CLL the overexpression of anti-apoptotic proteinsncer Biology 35 (2015) S78–S103 S89
has implicated in resistance to apoptosis [248]. Aberrant expres-
sion of Bcl-2 is common in CLL patients and is associated with poor
response to chemotherapy and decreased overall survival [249].
Moreover, Mcl-1 protein expression was  correlated with adverse
prognostic factors, such as disease stage, IgVH mutation status,
ZAP-70 positivity and CD38 expression [250] and, was  found to
be predictive of the clinical outcomes of CLL patients [251,252]. In
B-cells, several signals are involved in regulation of Bcl-2 family
proteins, including BCR, cytokine signaling and microRNA. CD40
signaling has been suggested to trigger up-regulation of the anti-
apoptotic proteins Mcl-1, A1 and Bcl-xL [253,254]. BCR signaling
has been reported to be able to regulate Mcl-1, through hyper-
activation of Akt [255] which also contributes to maintain cell
survival by phosphorylating and inactivating the pro-apoptotic
factor proteins Bad and Bim [256,257]. Given the key role that
anti-apoptotic proteins play in CLL, they became an attractive
target for the creation of novel therapeutic agents, such as anti-
sense methodology [258], small molecules mimicking the action
of BH3 domain [259], and microRNAs (mainly miRNA-15a and
miRNA-16-1) [260]. For several decades, front-line therapy for CLL
has been represented by treatment with alkylating agents and
purine analogs [261]. Recently, signiﬁcant clinical outcomes have
been achieved using chemo-immunotherapy, such as rituximab, a
chimeric monoclonal antibody against CD20, administrated in com-
bination with ﬂudarabine or ﬂudarabine plus cyclophosphamide
[262,263]. Nevertheless, the relapse remains problematic, partic-
ularly in older patients, thus the identiﬁcation of innovative and
speciﬁc agents against CLL remains of high interest [264].
Very interesting is the use of a cottonseed extract derivative,
gossypol, which acts as a BH3-mimetic, interfering with the func-
tions of Mcl-1, Bcl-2 and Bcl-xL proteins (from highest to lowest
afﬁnity) and displacing pro-death partners to induce apoptosis
[265–267]. However, despite this encouraging data and the abun-
dant literature describing the molecular mechanisms triggered by
phytochemicals to inhibit cell growth and induce apoptosis in can-
cer cells, only few of them entered clinical trials [268].
Acute promyelocytic leukemia (APML or APL for short) is a sub-
type of acute myelogenous leukemia (AML). APL is characterized
by an abnormal accumulation of immature granulocytes. The dis-
ease harbors chromosomal translocation involving the retinoic acid
receptor alpha (RAR  ˛ or RARA) gene and is distinguished from
other forms of AML  by its responsiveness to all-trans retinoic
acid therapy. The role of Bcl-2 proteins in apoptosis resistance
to retinoic acid therapy has been intensively investigated. It has
been shown that the ability of retinoid-induced cells to undergo
apoptosis depends on the level of expression and the functional
interaction between Bcl-2 and Bax [269]. Highlighting its signiﬁ-
cance, autophagy and Beclin 1, an autophagic protein, were shown
to be upregulated during the course of all trans retinoic acid
(ATRA)-induced neutrophil/granulocyte differentiation of an APL-
derived cell line. This induction of autophagy is associated with
downregulation of Bcl-2 and inhibition of mTOR activity. Further,
other studies have shown that a BH3 domain mimetic, JY-1-106,
which antagonizes the anti-apoptotic BCL-2 family members B-
cell lymphoma-extra large (BCL-xL) and myeloid cell leukemia-1
(MCL-1) alone and in combination with retinoids reduced cell via-
bility in HL-60 APL cells alone and in combination with retinoids.
The combination had the greatest impact on cell viability by stim-
ulating apoptosis. These studies indicate that dual BCL-xL/MCL-1
inhibitors and retinoids could work cooperatively in APL.
10. Role of different natural compounds (phytochemicals)
against apoptosis resistance
Since the early eighties, when apoptotic cell death appeared
on the stage of molecular cancer ﬁeld, scientists understood that
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ypassing apoptotic resistance resulted in novel therapeutic solu-
ions against cancer. These efforts successfully involved novel and
anonical anticancer drugs, but also stimulated the interest to
xplore the possibility that natural compounds may  re-sensitize
umor cells to pro-apoptotic drugs. However, many of the studies
hat followed have been limited to preclinical laboratory exper-
ments (largely conﬁned to cell lines). More importantly, it is
ifﬁcult to ﬁgure out how molecules that are structurally and func-
ionally different (i.e., stability, bioavailability, biotransformation
tc.) can behave similarly, and remove the resistance occurring in
ancer cells to apoptotic induction.
It must be imagined that a unique mechanism, common to many
hytochemicals, is responsible for their ability to re-establish the
ost sensitivity to apoptosis. The well-known antioxidant capacity
hared by the large majority of these compounds has been evoked
o explain the experimental evidence. However, the “antioxidant
ypothesis” is weakened by paradoxes and contradictions. In fact,
he scavenging activity of the phytochemicals against ROS chem-
cally converts them into oxidative products which display a high
eactivity toward thiols and can lead to the loss of protein function.
herefore, paradoxically, the net result between protection offered
y many phytochemicals and damage caused by its toxic prod-
cts may  weigh in favor of the latter. As an example, in lung cells,
uercetin efﬁciently protects against H2O2-induced DNA damage,
ut this positive effect is counteracted by the reduction in GSH
evel, an increase in LDH leakage and cytosolic-free calcium con-
entration [270]. Quercetin may  also form quercetin–quinone (QQ)
pecies when the molecule is employed as an antioxidant. QQ, like
ther semiquinone radicals and quinones, is toxic because of its
bility to arylate protein thiols. Protection against QQ may  arise
rom GSH which, when present at the right concentration, quickly
raps QQ [271]. Accordingly with this example, a pivotal review
rom Ursini’s group explains how the major mechanism of action
or nutritional antioxidants is the paradoxical oxidative activa-
ion of the Nrf2-Keap1 (nuclear factor erythroid 2-related factor
-Kelch-like ECH associated protein 1) signaling pathway, since
inetic constraints indicate that in vivo scavenging of radicals by
hese compounds is ineffective in antioxidant defense [272].
Nonetheless, although this preamble illustrate a critical chal-
enge in this area of research, recent studies have demonstrated
hat treatment with phytochemicals may  represent an applicable
herapeutic strategy to bypass apoptotic resistance in speciﬁc types
f cancers [273,274].
Pleiotropy”’ and “synergism” are two terms often associated to
he effects of natural compounds to explain their multiple bio-
ogical activities. The former refers to their ability to bind and
nterfere with the activity of several effectors that insist on one
r more pathways, converging on the same cellular process, for
xample apoptosis, cell cycle arrest, autophagy. The latter indi-
ates the property to enhance the efﬁcacy of chemotherapeutic
rugs in co-treatment protocols with the advantage to limit toxicity
or patients. Both features, pleiotropy and synergism, ﬁnd ratio-
ale applications in the physiopathology of cancer and is highly
elevant to some speciﬁc diseases such as CLL, a form leukemia
hich remains indolent for decades. In fact, patients with CLL
ay  survive for many years without any treatment because of
he relatively slow progression rate of the disease. This feature
akes CLL patients ideal models to test the pleiotropic properties
f natural chemo-preventers possessing limited toxicity. In fact,
n the temporal window during which patient’s remains asymp-
omatic, chronic administration of a speciﬁc phytochemical may
etard disease onset. Moreover, when the disease progresses to
linically relevant forms and requires pharmacological interven-
ions, the same compound can be introduced in the therapeutic
rotocol as adjuvant to synergistically improve the efﬁcacy of the
herapy. Supplementation with biologically active phytochemicalsncer Biology 35 (2015) S78–S103
or phytochemicals-enriched food may  represent an important
approach to modify the clinical progression of cancers. However, to
move from speculation to clinical application, further fundamen-
tal steps are required, such as well designed, randomized, control
clinical trials.
10.1. EGCG
Mechanistic studies suggest that polyphenols have multiple
intracellular targets, one of which is the proteasome complex
[275,276]. Several botanically derived agents such as green tea cat-
echins, isoﬂavones, anthocyanins, anthocyanidins, quercetin (3,3′,4
5,7-pentahydroxyﬂavone), apigenin and curcumin have been iden-
tiﬁed as potent proteasome inhibitors, with a more favorable
toxicity proﬁle compared to velcade and bortezomib and may  be
ideal candidates for therapeutic applicability in cancer chemo-
prevention and treatment. The goal of this section is to focus on
providing a model of a botanically derived agent green tea polyphe-
nol that has been demonstrated to induce apoptosis through
targeting of the ubiquitin/proteasome pathway.
Among the constituents of green tea extracts (GTE), laboratory
studies have identiﬁed EGCG as the most potent chemopreventive
agent which appears to affect a number of molecular processes
including induction of apoptosis and inhibition of tumor growth
and angiogenesis [277–280]. More recently EGCG has been found
to affect several cancer-related proteins including p27, Bcl-2 or
Bcr-Abl oncoproteins, Bax, matrix metalloproteinases (MMP-2 and
MMP-9) [281], the androgen receptor, EGF receptor, activator pro-
teins 1(AP1), and some cell cycle regulators [282–284]. Based on
their studies of GTE in cell culture systems, Adhami et al. [285]
were able to demonstrate that EGCG (in GTE) induces apoptosis,
cell growth inhibition and cyclin kinase inhibitor WAF-1/p21-
mediated cell cycle-dysregulation. Using cDNA microarrays, they
also observed the EGCG treatment of prostate cancer cells results
in induction of genes that functionally exhibit growth-inhibitory
effects and repression of genes that belong to the G-protein
signaling network. These data conﬁrm that GTEs exert potent and
selective in vitro and in vivo pro-apoptotic activity on prostate can-
cer cells. Although there are several mechanisms by which EGCG
may  operate in prostate carcinogenesis, EGCG has been demon-
strated to potently and selectively inhibit the proteasome activity
in intact human cells leading to the accumulation of IkB- and p27
proteins, and growth arrest [286]. This inhibition of proteasome
activity by EGCG occurred at or near physiological concentrations
similar to that found in the body ﬂuids of green tea drinkers.
Other studies have shown that a mixture of green tea polyphe-
nols (polyphenon E) is equally potent inhibiting the proteasome
activity as puriﬁed EGCG [287]. Polyphenon E preferentially inhibits
the proteasomal chymotrypsin-like activities over other activi-
ties; b. Polyphenon E inhibits proteasome activity in intact cells
in a concentration-dependent manner. Treatment of polyphenon
E, at all used concentrations in both cell lines, increased accumula-
tion of the proteasome target protein p27Kip1 in human multiple
myeloma and prostate cancer cells. Similar to puriﬁed EGCG, using
a cell-free proteasome assay it has been shown that Polyphenon
E signiﬁcantly inhibits the chymotrypsin-like activity of the puri-
ﬁed rabbit 20S proteasome with an IC50 value of 0.88 M.  To
investigate whether polyphenon E speciﬁcally inhibits the pro-
teasomal chymotrypsin-like activity, its effects on the PGPH-like
and trypsin-like activities of the puriﬁed 20S proteasome were
determined. Polyphenon E inhibited PGPH-like activity of the puri-
ﬁed rabbit 20S proteasome with an IC50 value of 7 M.  The IC50
value for trypsin-like activity was above 100 M,  thus demon-
strating that polyphenon E preferentially inhibits the proteasomal
chymotrypsin-like activities over other activities. The most sig-
niﬁcant study analyzed the effect of 2 mg/diet of Polyphenon E
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n a phase I/II clinical trial on asymptomatic CLL patients (Rai
tage 0 to II). The results of the study indicated that in 69% of
atients a substantial decline in absolute lymphocyte count (>20%)
nd/or reduction of lymphadenopathy (>30%) during the 6 months
f active treatment [288,289]. Also ﬂavopiridol, a semisynthetic
avonoidal alkaloid, originated from an Indian plant and known for
ts ability to inhibit cyclin-dependent kinases, achieved signiﬁcant
linical activity in patients with relapsed CLL, including those with
igh-risk genomic features and bulky lymphadenopathy [290,291].
These data strongly suggest that the proteasome, an important
arge multi subunit protease complex in the cell, is a cancer-related
olecular target of green tea catechins and that inhibition of the
roteasome activity by EGCG may  be the primary pathway by
hich tea catechins, speciﬁcally EGCG, induce prostate epithelial
ell apoptosis. This appears to be accomplished via the proteasome
nhibition pathway i.e.,  IB- protein expression, accumulation
f p27 proteins and decreasing NFB  DNA-binding activity, and
esulting in the inhibition of prostate cell survival and the induc-
ion of apoptosis, thereby decreasing progression from HGPIN to
rostate [292,293] – similar to the effects of bortezomib and vel-
ade (PS-341) [294–296].
The proteasome has been proven to be an excellent target for
eveloping anticancer drugs, but several side effects (including
ausea, fatigue, diarrhea, peripheral neuropathy, rapidly reversible
eduction in platelets, and reversible thrombocytopenia) have
een observed with bortezomib. Therefore, it is necessary to
dentify less toxic proteasome inhibitors with similar potency to
ortezomib or different novel proteasome inhibitors, as we  have
roposed in this study. Additionally, although it is clear that the
ster carbon of EGCG is important for mediating the proteasome-
nhibitory activity, EGCG is very unstable under physiological
onditions. Therefore, a series of EGCG analogs are evolving that
re aimed at improving stability and bioavailability of EGCG. Among
hem, peracetate-protected or the pro-drug of EGCG was found to
ave increased bioavailability, stability, and proteasome-inhibitory
ctivities against various human cancer cells and tumors com-
ared to EGCG, suggesting its potential use for cancer prevention
nd treatment [297]. The early laboratory and Phase I trials have
emonstrated GTPs, speciﬁcally EGCG, have a completely different
hemical structure from bortezomib. Most importantly, (−)-EGCG
nd other catechin mixtures at varying doses has been found to
e relatively better tolerated in clinical trials, in contrast to the
bserved AEs seen in the bortezomib trials, and thus appear to have
igniﬁcant potential to be tested in clinical trials.
In green tea, the catechin EGCG has been extensively studied
or the biological activities and cellular targets, among which the
roteasome attracts more attention [277]. Both naturally-occurring
−)-EGCG and synthetic enantiomer (+)-EGCG are able to potently
nd speciﬁcally inhibit the chymotrypsin-like activity of protea-
ome 5 subunit in an irreversible way with IC50 range 86–194 nM
n vitro and 1–10 M in vivo [280]. Of note, EGCG is able to inter-
ct with not only the 5 subunit in constitutive proteasome but
lso the 5i subunit in interferon- inducible immunoproteasome
referring to as BrAAP activity) with even higher afﬁnity [298]. Pre-
linical studies have demonstrated the chemosensitizing effect of
GCG and other catechins in vitro and in vivo. It has also been shown
hat EGCG reversed drug resistance by inhibiting the drug efﬂux
ransporter P-gp. For example, Kitagawa et al. [299] reported that
atechins increased the cellular accumulation of P-gp substrates
n human cervical epidermal carcinoma cells. The chemosensiti-
ation by EGCG through the inhibition of P-gp expression/activity
as also been validated in Caco-2 human intestinal adenocarci-
oma cells (which are often used as a model for intestinal transport
tudies mediated by P-gp) [300] and tamoxifen-resistant MCF-
 human breast cancer cells [301], as well as in the xenograft
ouse models using doxorubicin-resistant KB-A1 cells [302] orncer Biology 35 (2015) S78–S103 S91
doxorubicin-resistant BEL-7404/DOX hepatocarcinoma cells [303].
The study with tamoxifen-resistant MCF-7 cells also found that
EGCG was able to inhibit the activity of the BCRP transporter [304].
EGCG was  also reported to enhance the sensitivity of glioblas-
toma to temozolomide, and of prostate carcinoma to doxorubicin
[305], and of breast carcinoma to paclitaxel [306] in corresponding
ectopic or orthotopic xenograft mouse models. Furthermore, the
peracetate-protected prodrug of EGCG also exhibited a chemosen-
sitizing effect in the treatment of leukemia cells by augmenting the
efﬁcacy of conventional chemotherapy daunorubicin and cytosine
arabinoside [307]. A very recent study reported that polymer-
based nanoparticle of polyphenols EGCG and theaﬂavin retained
biological effectiveness with over 20-fold dose advantage than
EGCG/theaﬂavin in exerting anti-cancer effects and also enhanced
the potential of cisplatin in several different tumor cell types [308].
Encouraged by the preclinical results, a few studies were
conducted using green tea extract (GTE) as monotherapy or a
complementary/alternative medicine (CAM) in cancer patients.
Although its anticancer activity was unsatisfactory, the oral con-
sumption of GTE was well tolerated in these studies [309–311].
After a temporary suspension of EGCG in clinical trials by the US
Food and Drug Administration (FDA) for additional review of toxic-
ity, a tea extract named polyphenon E further proved the safety
of tea polyphenols. In a polyphenon E phase I clinical trial in
patients with asymptomatic Rai stage 0 to II chronic lymphocytic
leukemia, most patients showed declines in absolute lymphocyte
count and/or lymphadenopathy after daily oral consumption of
Polyphenon E. A phase II trial using 2 g polyphenon E twice a
day to evaluate its efﬁcacy showed that it was well tolerated by
patients with CLL and durable declines in the absolute lymphocyte
count and/or lymphadenopathy were observed in the majority of
patients [288]. Furthermore, two clinical studies using polyphenon
E in combination with erlotinib are currently ongoing in patients
with advanced non-small cell lung cancer and premalignant lesions
of the head and neck, respectively. The chemosensitizing effect of
polyphenon E in clinical settings remains to be determined. The
in vitro and in vivo studies suggest that tea polyphenols (espe-
cially EGCG) may  serve as powerful agents for reversing tumor drug
resistance and enhancing the efﬁcacy of chemotherapy.
10.2. Resveratrol
Isolated from the skin of red grapes, resveratrol received much
attention due to its association with the French Paradox (i.e., the
observation of low coronary disease incidence in high fat diet con-
suming French population who consume Red Wine-a supposedly
major source of resveratrol). Later on a number of laboratories
have demonstrated the anti-cancer activity of resveratrol in mul-
tiple tumor models. Studies have since shown that resveratrol can
reverse apoptosis resistance and also sensitize cancer cells to differ-
ent apoptosis inducing agents (chemotherapeutics). For example,
Sprouse and Herbert [312] very recently demonstrated that resver-
atrol can augment paclitaxel treatment in paclitaxel resistant breast
cancer cell line models. In another study Huq and colleagues [313]
showed that resveratrol can overcome chemoresistance in ovarian
cancer. In nasophyrangeal carcinoma, resveratrol has been shown
to cause expansion of ER, and ER caspase mediated apoptosis [314].
Similarly, it was demonstrated that resveratrol sensitizes tamox-
ifen in estrogen receptor resistance breast cancer models that show
epithelial-to-mesenchymal transition [315]. In a glioma model,
resveratrol was shown to suppress X linked inhibitor of apop-
totic proteins [316]. While Díaz-Chávez [317] utilized a proteomic
approach to investigate the mechanism of resveratrol mediated
chemosensitization and highlighted the role of hsp27 (at least in
the model they tested).
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Other studies support the apoptosis and necrosis inducing
ffects of resveratrol in different cancer models. Aside from resver-
trol, studies have also focused on its biological analog piceatannol
s well. For example, Farrand and colleagues [318] demonstrated
hat piceatannol enhances cisplatin sensitivity in ovarian cancer via
odulation of p53, X-linked inhibitor of apoptosis protein (XIAP),
nd mitochondrial ﬁssion. Several natural compounds have been
mployed to assess their anti-apoptotic effects in in vitro mod-
ls of CLL. For example, resveratrol (3,4′,5-trihydroxystilbene), a
hytoalexin well known for its healthy properties, induced apo-
tosis in WSU-CLL cells (derived from a CLL patient resistant to
udarabine) and in B cells isolated from CLL patients; instead, nor-
al  peripheral blood mononuclear cells were slightly affected. The
ffect of this compound, used at 10–50 M concentration, was
orrelated to a down-regulation of two anti-apoptotic proteins,
nducible nitric oxide synthase and Bcl-2 [319,320]. Recently, it has
een reported that oral administration of resveratrol (5 g/day) for 4
eeks, to three CLL patients, decreased circulating white blood cell
ounts and directly lowered O-linked -N-acetylglucosamine (O-
lcNAc) levels in leukemic cells through proteasomal activation;
his is an interesting result considering that CLL cells are char-
cterized by high levels of proteins that are post-translationally
odiﬁed by O-GlcNAc moieties [321]. Resveratrol, in combination
ith quercetin, induced apoptosis and cell cycle arrest in G0/G1 in
uman 232B4 cell line derived from CLL [322]. Collectively, these
tudies very clearly demonstrate that grape derivative resveratrol
nd its analogs can either induce apoptosis by themselves or can
ensitize resistant cells to apoptosis inducers.
0.3. Curcumin
Curcumin, which is the major component of turmeric has been
sed in folklore medicine for centuries. The ﬁrst reports on anti-
ancer activity of curcumin were reported in 1985 [323]. Since
hen more than 3000 studies have been reported on the different
nti-cancer mechanisms of curcumin and related analogs (numbers
rom PubMed search). Numerous studies have shown the apoptotis
nducing effects of curcumin and analogs in cancer cell lines (the
eaders are referred to several outstanding reviews in the literature
324]).
In primary B-CLL cells curcumin induced apoptosis with a mean
C50 of 5.5 M,  fourfold lower than the EC50 observed in normal
ononuclear cells (21.8 M).  The molecule blocks NF-B signaling,
robably through inhibition of IB [325]. Some authors observed an
nduction of apoptosis in primary B-cells using curcumin in associa-
ion with other natural compounds, such as rapamycin and EGCG. In
he former case, the effect was associated with a decreased expres-
ion of Bcl-2 and an increased level of the pro-apoptotic factor Bax
326]. Sequential administration of curcumin and EGCG led to a sub-
tantial increase in B-cells death, overcoming stromal protection
327,328]. These are some examples showing the potency of cur-
umin in overcoming resistance to apoptosis. The synergism shown
y curcumin with other natural compounds need to be examined
n greater details in order to move these combinations in clinical
tudies.
0.4. Quercetin
Quercetin a phytochemical found in a broad range of fruits,
egetables and beverage, is widely known for its antioxidant,
nti-inﬂammatory, anti-proliferative and apoptotic effects both
n cell culture and animal models [329,330]. Quercetin at rela-
ively low concentrations (10–20 M)  is able to down-regulate
cl-1 and thus sensitize to apoptosis the B-cells isolated from CLL
atients [331,332], with the maximal effect observed in combined
reatments with apoptotic inducers (see below). Moreover, recentncer Biology 35 (2015) S78–S103
studies have reported that quercetin affects Hh, Wnt, as well as
Notch signaling, emphasizing the potential efﬁcacy of the molecule
against CLL [333].
10.5. Isothiocyanates
Several studies have documented the cancer-preventive activity
of many isothiocyanates (ITCs), occurring in cruciferous vegetables.
They produce their anticancer effects through distinct but intercon-
nected signaling pathways [334]. Sulforaphane, a well-studied ITC,
restored chemosensitivity to DOX in mouse ﬁbroblasts with p53
mutated at codon 220 [335]. The clinical pattern observed for the
above reported mutation sustains a strong oncogenic potential and
a lack of chemotherapy response. Sulforaphane was able to increase
the efﬁcacy of DOX, allowing its administration at levels within
the concentration range clinically achievable [336]. The mecha-
nism by which Sulforaphane reversed DOX resistance involves a
rapid depletion of glutathione that renders cells more susceptible
to DOX-induced oxidative stress, stress-induced damage, and apo-
ptosis induction. The same study has shown that, pre-treatment
with N-acetyl-cysteine, a glutathione precursor, prevented Sul-
foraphane plus DOX-induced apoptosis. Since the clinical doses
of DOX currently being used during therapy are associated with
severe cardiotoxicity [337], Gupta et al. [338] analyzed the ability
of phenylethyl ITC (PEITC) to enhance the cytotoxic effects of low
(sub-toxic) concentrations of DOX in human breast carcinoma cells
stably transfected with the oncogene HER2. PEITC increased the
cytotoxicity of DOX. Moreover, DOX treatment suppressed HER2
expression modestly, whereas the combination of PEITC with DOX
markedly decreased the expression of HER2 and the phosphoryla-
tion of STAT3, known to play a critical role in the expression of cell
proliferative pathways [339]. Consistently, combination treatment
showed increased cleavage of caspase 3 and PARP as compared to
individual treatment indicating apoptosis. In colorectal cancer cells,
co-administration of Sulforaphane potentiated the growth inhibi-
tion activity of oxaliplatin through a reduction of intracellular ATP
levels, activation of caspase-3, DNA fragmentation, and PARP cleav-
age [340]. Cisplatin was also tested in combination with PEITC in
endometrial cancer cells [341] or with BITC in leukemia cells [342].
The combination therapy induced an increase in caspase-3 activity
and increased levels of cleaved PARP. Such effects were not cell-
speciﬁc since these results could also be observed in breast cancer
cells. The sensitization induced by ITCs was  partly mediated by ERK
and Noxa activation. Interestingly, no effect was found in normal
breast cells or lymphocytes.
ITCs also enhanced the efﬁcacy of cisplatin when used against
human non-small cell lung cancer cells [343]. Neither cellular plat-
inum accumulation nor DNA platination accounts for this effect.
Protein binding is important for the induction of apoptosis by ITCs
[344]. ITCs covalently modify cysteine residues in tubulin, resulting
in tubulin conformational changes, disruption of microtubule poly-
merization, and ultimately apoptosis. Tubulin-binding agents such
as paclitaxel are commonly used in combination with platinum
drugs to treat non-small cell lung cancer [345]. Thus, -tubulin
depletion may  correlate and be important for sensitization to plat-
inum compounds by ITCs.
Taken together, the evidence reported above indicates that
EGCG and ITCs have an enormous potential for enhancing tumor
cell sensitivity to therapy. However, some recent results sound a
cautionary note. EGCG and ITCs are able to increase Nrf2 expres-
sion [346], a key transcription factor inducing a cytoprotective gene
array. Since many standard chemotherapeutic agents are cytotoxic,
their cytotoxic effects can be abrogated by tumor cells by upregu-
lation of Nrf2 signaling, thereby yielding a more aggressive tumor
[347]. Even if pharmacologic induction of Keap1–Nrf2-signaling
axis allows for pulsed rather than permanent induction [348],
 in Cancer Biology 35 (2015) S78–S103 S93
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urther studies are necessary before suggesting the use of EGCG
r ITCs in patients with established cancers who are undergoing
hemotherapy treatment.
0.6. Marine derived agents with apoptosis inducing properties
Aside from different plant derived natural products, nature
as bestowed many other types of anti-cancer compounds from
arine sources as well. A key word search on ‘Marine anticancer
gents’ reveals more than 3000 hits in PubMed. Many of these
tudies directly point to the apoptotic inducing potential of marine
erived compounds in cancer cell lines and animal xenograft mod-
ls [349–358]. For those seeking additional detail in this area, we
efer the reader to an excellent literature review on the topic [359].
In summary, there is ample laboratory and early phase clinical
vidence demonstrating that natural agents (both plant and marine
erived) can impact important signaling pathways associated with
poptosis. However, a lot remains to be learned on their exact
echanism of action especially in relation to overcoming resis-
ance to apoptosis. Further studies on these agents are anticipated
o enhance our knowledge that in turn will drive their rapid clinical
se in combination with standard chemotherapeutics or targeted
herapies against therapy resistant cancers.
1. Broad spectrum approach to obtain synergies between
arious different approaches
Given that the heterogeneity that is present in most cancers,
t is our assumption that the complete arrest of the various sub-
opulations of immortalized cells in any given cancer will require
imultaneous actions on mechanisms that are important for several
spects of cancer’s biology. We  therefore believe that it is impor-
ant to be able to anticipate synergies that might be achieved by
cting on speciﬁc targets and with speciﬁc approaches (i.e., when
ontemplating an approach aimed at a broad-spectrum of targets).
ccordingly, in this review, we also explored cross-hallmark rela-
ionships that have been found between the prioritized target sites
nd the approaches that we identiﬁed in this review.
Speciﬁcally, when evidence in the literature showed that the
argets and approaches that we identiﬁed as relevant for apopto-
is resistance were also therapeutically relevant for other aspects
f cancer’s biology (i.e., anti-carcinogenic) we noted them as hav-
ng “complementary” cross-hallmark effects. While those that were
ound to have pro-carcinogenic actions were noted as having “con-
rary” effects. In instances where reports on relevant actions in
ther aspects of cancer biology were mixed (i.e., reports showing
oth pro-carcinogenic potential and anti-carcinogenic potential),
he term “controversial” was used. Finally, in instances where no
iterature support was found to document the relevance of a target
ite or approach in a particular aspect of cancer’s biology, we doc-
mented this as “no known relationship”. These validation results
re shown below in tabular form in Tables 1 and 2.
It is predicted that future cancer therapeutics will be based on
etwork pharmacology strategies that will likely involve empir-
cal testing of mixtures of constituents. Therefore, we wanted to
reate a starting point for other researchers who might be consid-
ring translational projects. We  anticipated interest in approaches
eported to exhibit a large number of anti-carcinogenic actions
cross the hallmarks and we anticipated that a lack of pro-
arcinogenic potential might be important to identify in advance
since targets or approaches that have been shown to exert pro-
arcinogenic actions would potentially represent a confounding
nd unwanted inﬂuence/factor in empirical research).
Our cross validation exercise showed that in some instances,
he underlying evidence used to support the indication of a Ta
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Table 2
Relationships of the approaches to different cancer hallmarks.
Approaches Gossypol EGCG UMI-77 Triptolide Selinexor
Other cancer hallmarks
Genomic instability
Sustained proliferative signaling 0 + [452,453] 0 0 0
Tumor promoting inﬂammation +[454,455] + [456,457] + [32] + [458,459] 0
Evasion of anti-growth signaling +[460,461] + [462,463] 0 + [464,465] 0
Replicative immortality +[466,467] +[468–470] + [32] + [471] 0
Dysregulated metabolism +[472,473] + [474,475] 0 + [476] 0
Immune system evasion + [477] + [478] 0 +[479–481] 0
Angiogenesis 0 + [482,483] 0 − [484] 0
Tissue invasion and metastasis + [454] + [485] 0 + [486] 0
Tumor microenvironment + [487] + [488] + [32] + [489,490] +[491,492]
+ [493] + [483,494] + [32] + [495,496] + [497]
Selected approaches were evaluated for reported actions in other cancer hallmark areas. Approaches that were found to have complementary, anti-carcinogenic actions in
a  particular hallmark area were were indicated with “+”, while approaches that were found to have pro-carcinogenic actions in a particular hallmark area were indicated
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sith  “−”. In instances where reports on relevant actions in other hallmarks were 
ymbol “+/-” was used. Finally, in instances where no literature support was found
ocumented this as “0”. These cross-hallmark relationships are reported in the upp
ross-hallmark relationship was robust, consisting of multiple
tudies involving detailed in vitro and in vivo ﬁndings. In other
nstances, however, the underlying evidence that was used to
eport the existence of a cross-hallmark relationship was  quite
eak (e.g., consisting of only a single in vitro study involving a single
ell-type). Additionally, there are examples of approaches that are
nown to exert different effects at different dose levels and in dif-
erent tissues but dose-levels and cell/tissue types were not used
o discriminate when gathering together these reported actions.
onetheless, given that the overarching goal in this project was  to
reate a foundation that would allow researchers to look systemat-
cally across the literature in each of these areas, the tables should
erve as a useful starting point as long as they are approached with
aveats in mind and a degree of caution. Essentially, we believe that
his heuristic should be useful to consider synergies that might be
nticipated in testing that involves certain targets and/or mixtures
f chemical constituents that are being considered for therapeutic
ffects.
2. Conclusions and future directions
Resistance to apoptosis is multi-factorial involving the interac-
ion of various signaling pathways at multiple levels. Therefore,
he use of single pathway targeted agents to commit cancer cells
o undergo apoptosis is not a feasible strategy (except in iso-
ated cases). Hence, this requires a careful selection of treatment
trategies that are based on a comprehensive understanding of the
iological networks involved in resistance. This article presents
ome of the major genetic and epigenetic drivers of apopto-
is resistance and provides a list of prioritized targets and the
pproaches that can be utilized against them to overcome de novo
r acquired resistance. In this review, ﬁrst we discussed how Bcl-2
amily proteins play critical role in the biology of apoptosis acti-
ation/resistance. We  presented knowledge on the development
f agents such as gossypol and synthetic compounds particularly
BT-737 that have entered clinical trials. Additionally, we also
ighlighted problems associated with Bcl-2 inhibition and the
evelopment of resistance by one of its family member Mcl-1 mak-
ng it an attractive target. In this direction, speciﬁc drugs against
cl-1 are being investigated in the pre-clinical setting and some of
hese agents are expected to enter clinical evaluation in the near
uture. Additional cell death mechanisms such as autophagy and
ecrosis were also discussed and strategies, particularly the use
f natural agents such EGCG were highlighted. The role of chap-
rone protein hsp70 in apoptosis resistance was evaluated and
uggestions to overcome this critical protein marker using natural (i.e., reports showing both anti-carcinogenic and pro-carcinogenic potential), the
cument the relevance of an approach in a particular aspect of cancer’s biology, we
s of the table.
products were presented. The article also discusses the molecular
mechanisms that support the resistance to apoptosis in different
cancers such as glioblastoma, multiple myeloma, CLL, prostate can-
cer, breast cancer, colon cancer and pancreatic cancer. The role of
epigenetic players, particularly miRNAs, in the development of apo-
ptosis resistance was  also highlighted. The cross-validation tables
(Tables 1 and 2) are offered here as a simple heuristic frame-
work that is intended to help researchers approach the topic of
anticipated synergies. Although, these attempts do not represent a
homogenous set of underlying data, it is hoped that it can serve as a
starting point for the translational research that will be needed for
the design of effective natural product based therapies. Rigorous
experimentation will obviously be needed to determine whether
or not actual synergies between the identiﬁed approaches emerge
that can be predicted and clinically applied. A much broader range
of targets overall may  be the only chance we  will have to address
cancer associate heterogeneity. It is a promising approach, but a
considerable amount of encompassing research needs to follow
to determine methodological validity. Collectively, these unique
targets and speciﬁc strategies may  bring forward a broad form
of therapy to overcome resistance to apoptosis resulting in better
treatment outcome in patients suffering from cancer.
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